- Worldcom Public Relations Group Expands LATAM Region
Dec 14, 2022 · businesswire.com
NEW YORK--(BUSINESS WIRE)--The Worldcom Public Relations Group (Worldcom), the leading global partnership of independent public relations firms, announced today that it has voted Estrategia Relaciones Públicas., Tegucigalpa, Honduras into its partnership. “Estrategia is an outstanding agency and an important addition to both our LATAM region and our global partnership,” said Luis Avellaneda, Managing Director, Realidades (Lima, Peru), and Worldcom’s LATAM Recruitment Chair. “They are highly respected and recognized in Honduras, the region and across LATAM. This is an important addition to our collaborative partnership and our significant presence across the LATAM region – extending our ability to serve Worldcom partners’ existing clients across the region while providing prospects comprehensive reach and resources.” Over its 15 year history, Estrategia Relaciones Públicas has gained a reputation for highly differentiated, impactfully executed strategic communications campaigns and crisis management efforts. As a boutique agency of senior professionals, the team works across a broad spectrum of market sectors, specializing in media relations, crisis counsel and strategic communications. Estrategia Relaciones Públicas is a communication firm of integrated strategists in order to generate valuable Public Relations with companies from different industries; Estrategia reinforces the practices of companies aimed at creating, caring for and sustaining the positive image of their brand over time, as if it were their own. “We provide a great value service for our clients. Under the pillars of ethics, excellence, empathy and empowerment to overcome the challenges that arise in the daily evolution of communication events that companies currently face in the Central American region," stated Luis Felipe Sánchez, Regional Director. Welcoming Estrategia to The Worldcom Public Relations Group marks the completion of a rigorous Worldcom partner recruitment and vetting process. It ensures the compatibility of the agency applying for partnership, along with their ability to meet the standards of trust and collaboration that have defined The Worldcom PR Group since its founding in 1988. As the newest partner, Estrategia joins a robust group of global partners who openly share knowledge and best practices, utilize the partnership to meet expanding client roles, and collaborate on new opportunities scaled to the local, regional, and global needs of any Worldcom partner client or prospect. About Estrategia Relaciones Públicas Since 2008 we serve as an agency specialized in relationship with the audience and strategic communication, working with different industries and brands both national, regional and global such as education, fast food franchises, dairy industry, food and beverage, banking, ONGS and foundations, energy and construction, automotive, real state, Airlines, pharmaceutical, technology, farming, entertaining, hygiene and health among others. We firmly believe that we develop under the concept of “We substitute experience for excellence”. Learn more about Estrategia Relaciones Públicas at www.estrategiahn.com or by calling + (504) 2205-9022. Connect with Estrategia PR on: https://www.facebook.com/EstrategiaHN https://twitter.com/estrategia_hn https://www.linkedin.com/company/estrategiahn/ https://www.instagram.com/estrategiahn/ About The Worldcom Public Relations Group The Worldcom Public Relations Group is the world’s leading partnership of independently owned public relations firms, with 143 offices employing some 2,000 staff in 115 cities across six continents. In total, Worldcom partners reported combined revenue of US$300+ million last year from 3,034 clients. Established in 1988, the group was formed so that the strongest, most capable independent firms could deliver immediate impact and sustained value through the intelligent use of communications – wherever in the world a client needs support. Partners serve national, international, and multinational clients, while retaining the flexibility and client-service focus inherent in independent agencies. Through Worldcom, clients have on-demand access to in-depth communications expertise from professionals who understand the language, culture and customs of the geographic areas in which they operate. Learn more about Worldcom at www.worldcomgroup.com or by calling 1-800-955-9675. Connect with Worldcom PR Group on Facebook and LinkedIn. Learn more about Worldcom at www.worldcomgroup.com or call Todd Lynch at 1-800-955-9675.
- WORLDCOM PUBLIC RELATIONS GROUP EXPANDS LATAM REGION
Dec 14, 2022
NEW YORK--(BUSINESS WIRE)--THE WORLDCOM PUBLIC RELATIONS GROUP (WORLDCOM), THE LEADING GLOBAL PARTNERSHIP OF INDEPENDENT PUBLIC RELATIONS FIRMS, ANNOUNCED TODAY THAT IT HAS VOTED ESTRATEGIA RELACIONES PÚBLICAS., TEGUCIGALPA, HONDURAS INTO ITS PARTNERSHIP. “ESTRATEGIA IS AN OUTSTANDING AGENCY AND AN IMPORTANT ADDITION TO BOTH OUR LATAM REGION AND OUR GLOBAL PARTNERSHIP,” SAID LUIS AVELLANEDA, MANAGING DIRECTOR, REALIDADES (LIMA, PERU), AND WORLDCOM’S LATAM RECRUITMENT CHAIR. “THEY ARE HIGHLY RESPECTED AND RECOGNIZED IN HONDURAS, THE REGION AND ACROSS LATAM. THIS IS AN IMPORTANT ADDITION TO OUR COLLABORATIVE PARTNERSHIP AND OUR SIGNIFICANT PRESENCE ACROSS THE LATAM REGION – EXTENDING OUR ABILITY TO SERVE WORLDCOM PARTNERS’ EXISTING CLIENTS ACROSS THE REGION WHILE PROVIDING PROSPECTS COMPREHENSIVE REACH AND RESOURCES.” OVER ITS 15 YEAR HISTORY, ESTRATEGIA RELACIONES PÚBLICAS HAS GAINED A REPUTATION FOR HIGHLY DIFFERENTIATED, IMPACTFULLY EXECUTED STRATEGIC COMMUNICATIONS CAMPAIGNS AND CRISIS MANAGEMENT EFFORTS. AS A BOUTIQUE AGENCY OF SENIOR PROFESSIONALS, THE TEAM WORKS ACROSS A BROAD SPECTRUM OF MARKET SECTORS, SPECIALIZING IN MEDIA RELATIONS, CRISIS COUNSEL AND STRATEGIC COMMUNICATIONS. ESTRATEGIA RELACIONES PÚBLICAS IS A COMMUNICATION FIRM OF INTEGRATED STRATEGISTS IN ORDER TO GENERATE VALUABLE PUBLIC RELATIONS WITH COMPANIES FROM DIFFERENT INDUSTRIES; ESTRATEGIA REINFORCES THE PRACTICES OF COMPANIES AIMED AT CREATING, CARING FOR AND SUSTAINING THE POSITIVE IMAGE OF THEIR BRAND OVER TIME, AS IF IT WERE THEIR OWN. “WE PROVIDE A GREAT VALUE SERVICE FOR OUR CLIENTS. UNDER THE PILLARS OF ETHICS, EXCELLENCE, EMPATHY AND EMPOWERMENT TO OVERCOME THE CHALLENGES THAT ARISE IN THE DAILY EVOLUTION OF COMMUNICATION EVENTS THAT COMPANIES CURRENTLY FACE IN THE CENTRAL AMERICAN REGION," STATED LUIS FELIPE SÁNCHEZ, REGIONAL DIRECTOR. WELCOMING ESTRATEGIA TO THE WORLDCOM PUBLIC RELATIONS GROUP MARKS THE COMPLETION OF A RIGOROUS WORLDCOM PARTNER RECRUITMENT AND VETTING PROCESS. IT ENSURES THE COMPATIBILITY OF THE AGENCY APPLYING FOR PARTNERSHIP, ALONG WITH THEIR ABILITY TO MEET THE STANDARDS OF TRUST AND COLLABORATION THAT HAVE DEFINED THE WORLDCOM PR GROUP SINCE ITS FOUNDING IN 1988. AS THE NEWEST PARTNER, ESTRATEGIA JOINS A ROBUST GROUP OF GLOBAL PARTNERS WHO OPENLY SHARE KNOWLEDGE AND BEST PRACTICES, UTILIZE THE PARTNERSHIP TO MEET EXPANDING CLIENT ROLES, AND COLLABORATE ON NEW OPPORTUNITIES SCALED TO THE LOCAL, REGIONAL, AND GLOBAL NEEDS OF ANY WORLDCOM PARTNER CLIENT OR PROSPECT. ABOUT ESTRATEGIA RELACIONES PÚBLICAS SINCE 2008 WE SERVE AS AN AGENCY SPECIALIZED IN RELATIONSHIP WITH THE AUDIENCE AND STRATEGIC COMMUNICATION, WORKING WITH DIFFERENT INDUSTRIES AND BRANDS BOTH NATIONAL, REGIONAL AND GLOBAL SUCH AS EDUCATION, FAST FOOD FRANCHISES, DAIRY INDUSTRY, FOOD AND BEVERAGE, BANKING, ONGS AND FOUNDATIONS, ENERGY AND CONSTRUCTION, AUTOMOTIVE, REAL STATE, AIRLINES, PHARMACEUTICAL, TECHNOLOGY, FARMING, ENTERTAINING, HYGIENE AND HEALTH AMONG OTHERS. WE FIRMLY BELIEVE THAT WE DEVELOP UNDER THE CONCEPT OF “WE SUBSTITUTE EXPERIENCE FOR EXCELLENCE”. LEARN MORE ABOUT ESTRATEGIA RELACIONES PÚBLICAS AT WWW.ESTRATEGIAHN.COM OR BY CALLING + (504) 2205-9022. CONNECT WITH ESTRATEGIA PR ON: HTTPS://WWW.FACEBOOK.COM/ESTRATEGIAHN HTTPS://TWITTER.COM/ESTRATEGIA_HN HTTPS://WWW.LINKEDIN.COM/COMPANY/ESTRATEGIAHN/ HTTPS://WWW.INSTAGRAM.COM/ESTRATEGIAHN/ ABOUT THE WORLDCOM PUBLIC RELATIONS GROUP THE WORLDCOM PUBLIC RELATIONS GROUP IS THE WORLD’S LEADING PARTNERSHIP OF INDEPENDENTLY OWNED PUBLIC RELATIONS FIRMS, WITH 143 OFFICES EMPLOYING SOME 2,000 STAFF IN 115 CITIES ACROSS SIX CONTINENTS. IN TOTAL, WORLDCOM PARTNERS REPORTED COMBINED REVENUE OF US$300+ MILLION LAST YEAR FROM 3,034 CLIENTS. ESTABLISHED IN 1988, THE GROUP WAS FORMED SO THAT THE STRONGEST, MOST CAPABLE INDEPENDENT FIRMS COULD DELIVER IMMEDIATE IMPACT AND SUSTAINED VALUE THROUGH THE INTELLIGENT USE OF COMMUNICATIONS – WHEREVER IN THE WORLD A CLIENT NEEDS SUPPORT. PARTNERS SERVE NATIONAL, INTERNATIONAL, AND MULTINATIONAL CLIENTS, WHILE RETAINING THE FLEXIBILITY AND CLIENT-SERVICE FOCUS INHERENT IN INDEPENDENT AGENCIES. THROUGH WORLDCOM, CLIENTS HAVE ON-DEMAND ACCESS TO IN-DEPTH COMMUNICATIONS EXPERTISE FROM PROFESSIONALS WHO UNDERSTAND THE LANGUAGE, CULTURE AND CUSTOMS OF THE GEOGRAPHIC AREAS IN WHICH THEY OPERATE. LEARN MORE ABOUT WORLDCOM AT WWW.WORLDCOMGROUP.COM OR BY CALLING 1-800-955-9675. CONNECT WITH WORLDCOM PR GROUP ON FACEBOOK AND LINKEDIN. LEARN MORE ABOUT WORLDCOM AT WWW.WORLDCOMGROUP.COM OR CALL TODD LYNCH AT 1-800-955-9675.
- Hasura to Allow Anyone to Turn Any Data Source into a GraphQL API
Jun 28, 2022 · businesswire.com
SAN FRANCISCO--(BUSINESS WIRE)--GraphQL innovation leader Hasura today announced, during Hasura CEO Tanmai Gopal’s keynote at HasuraCon ‘22, a series of new innovations including a new Hasura GraphQL Data Connector (GDC) SDK that allows developers to extend Hasura to bring GraphQL to their favorite data sources. In addition, Hasura also announced availability of Hasura Cloud Enterprise in AWS Marketplace, general availability of Hasura Cloud deployment on Google Cloud, general availability of GitHub integrations on Hasura Cloud, MS SQL event triggers, streaming subscriptions and support for OpenTelemetry Traces in the Hasura Cloud and Enterprise Editions. To attend the full conference, being held June 28-30, register here. Hasura makes web application and API development faster than ever before by eliminating bottlenecks to data access. It provides a declarative approach to modeling and securing data from supported data sources by instantly providing a flexible, performant and production-ready data API. The early release of Hasura’s GDC SDK furthers Hasura’s goal of allowing enterprise teams to connect to all types of data sources to Hasura, and to getting a powerful GraphQL API on their data. Hasura’s GDC specification and SDK allows developers to extend Hasura’s GraphQL API capabilities without waiting for Hasura to natively support their data sources. Using the SDK, developers can build plug-ins for all types of data sources, including proprietary or legacy data sources that might be unique to their enterprise environments as well as new and emerging database technologies. With this early release SDK, Hasura invites enterprise teams and the community to work together toward understanding and activating their most important data sources. This furthers Hasura’s goal to activate data wherever it is and to continuously evolve with the industry’s needs as it leverages new types of data sources. It gets users up and running with a production-ready, real-time API in minutes, saving weeks or months of development time. “The developer experience gap for data-driven apps continues to widen as enterprises are faced with integrating an ever-growing number of data sources,” said James Governor, co-founder of RedMonk. “Hasura is designed to address this gap by enabling engineering teams to get up and running with the latest cloud-hosted, custom and legacy data sources to build new APIs and apps quickly.” Additional announcements by Hasura today include: Hasura Cloud Enterprise Availability in AWS Marketplace, a digital catalog of software listings that makes it easy to find, test, buy and deploy software that runs on Amazon Web Services (AWS), makes Hasura more broadly and easily available to users worldwide. AWS Marketplace is the first cloud marketplace in which Hasura is available. The availability of Hasura Cloud Enterprise in AWS Marketplace makes it easier for customers to increase the speed of development for their own products through GraphQL data APIs. General Availability of Hasura on Google Cloud lets Hasura Cloud and Cloud Enterprise users with databases and other services on Google Cloud create Hasura projects on Google Cloud, reducing egress charges and improving performance due to co-location. Hasura customers using Virtual Private Cloud (VPC) on Google Cloud are now able to peer with their own VPCs, enabling their workloads to communicate internally. This increases security as user traffic remains in the Google Cloud network, never traversing the public internet. Streaming Subscriptions API allows users to build high-performance real-time apps using Hasura, streaming data to their clients in batches and updating data in real-time. This expands on Hasura’s previous real-time API, which is built with a live-query interface. MS SQL Server Event Triggers Support enables users to connect business logic APIs with Hasura to integrate asynchronous backend logic into their applications by calling webhooks on table events such as insert/update/delete for SQL Server data sources. This expands on previous support for Postgres and enables users to connect business logic APIs with Hasura to integrate asynchronous backend logic into their applications. GitHub integration General Availability increases ease of CI/CD pipeline management, reliability and development speed by helping developers move quickly and easily between local development and Hasura Cloud. A preview apps feature (in beta) enables users to quickly test changes to metadata migrations and link to GitHub PRs to automatically deploy with every push. Support for OpenTelemetry Traces in Hasura Cloud and Hasura Enterprise Editions gives customers enhanced observability through traces in the OpenTelemetry format via OpenTelemetry compatible agents and direct connections with APM tools such as New Relic and Dynatrace. This enables them to provide better reliability and end user experiences for their mission-critical applications through rapid problem diagnosis. “We see the inevitability of data continuing to explode across three fronts – the volume of data, the type of data and the things we’re doing with the data, including transactional, analytical and ML/AI,” said Gopal. “Our mission is to be your infrastructure partner as you’re thinking about how to make your organization’s data available and as you’re designing a stack to support next-gen product development and modernization. We do this by helping you activate the data you already have and by ensuring that we’re continuously evolving to support the rapid explosion of use-cases. The innovations announced today are a key step toward achieving that mission.” About Hasura Hasura is helping to build the modern world of globally relevant, data-driven applications and APIs. Hasura’s range of data access solutions helps organizations accelerate product delivery by instantly connecting data and services to applications with GraphQL APIs. For more information, go to: https://hasura.io or follow @HasuraHQ on Twitter.
- HASURA TO ALLOW ANYONE TO TURN ANY DATA SOURCE INTO A GRAPHQL API
Jun 28, 2022
SAN FRANCISCO--(BUSINESS WIRE)--GRAPHQL INNOVATION LEADER HASURA TODAY ANNOUNCED, DURING HASURA CEO TANMAI GOPAL’S KEYNOTE AT HASURACON ‘22, A SERIES OF NEW INNOVATIONS INCLUDING A NEW HASURA GRAPHQL DATA CONNECTOR (GDC) SDK THAT ALLOWS DEVELOPERS TO EXTEND HASURA TO BRING GRAPHQL TO THEIR FAVORITE DATA SOURCES. IN ADDITION, HASURA ALSO ANNOUNCED AVAILABILITY OF HASURA CLOUD ENTERPRISE IN AWS MARKETPLACE, GENERAL AVAILABILITY OF HASURA CLOUD DEPLOYMENT ON GOOGLE CLOUD, GENERAL AVAILABILITY OF GITHUB INTEGRATIONS ON HASURA CLOUD, MS SQL EVENT TRIGGERS, STREAMING SUBSCRIPTIONS AND SUPPORT FOR OPENTELEMETRY TRACES IN THE HASURA CLOUD AND ENTERPRISE EDITIONS. TO ATTEND THE FULL CONFERENCE, BEING HELD JUNE 28-30, REGISTER HERE. HASURA MAKES WEB APPLICATION AND API DEVELOPMENT FASTER THAN EVER BEFORE BY ELIMINATING BOTTLENECKS TO DATA ACCESS. IT PROVIDES A DECLARATIVE APPROACH TO MODELING AND SECURING DATA FROM SUPPORTED DATA SOURCES BY INSTANTLY PROVIDING A FLEXIBLE, PERFORMANT AND PRODUCTION-READY DATA API. THE EARLY RELEASE OF HASURA’S GDC SDK FURTHERS HASURA’S GOAL OF ALLOWING ENTERPRISE TEAMS TO CONNECT TO ALL TYPES OF DATA SOURCES TO HASURA, AND TO GETTING A POWERFUL GRAPHQL API ON THEIR DATA. HASURA’S GDC SPECIFICATION AND SDK ALLOWS DEVELOPERS TO EXTEND HASURA’S GRAPHQL API CAPABILITIES WITHOUT WAITING FOR HASURA TO NATIVELY SUPPORT THEIR DATA SOURCES. USING THE SDK, DEVELOPERS CAN BUILD PLUG-INS FOR ALL TYPES OF DATA SOURCES, INCLUDING PROPRIETARY OR LEGACY DATA SOURCES THAT MIGHT BE UNIQUE TO THEIR ENTERPRISE ENVIRONMENTS AS WELL AS NEW AND EMERGING DATABASE TECHNOLOGIES. WITH THIS EARLY RELEASE SDK, HASURA INVITES ENTERPRISE TEAMS AND THE COMMUNITY TO WORK TOGETHER TOWARD UNDERSTANDING AND ACTIVATING THEIR MOST IMPORTANT DATA SOURCES. THIS FURTHERS HASURA’S GOAL TO ACTIVATE DATA WHEREVER IT IS AND TO CONTINUOUSLY EVOLVE WITH THE INDUSTRY’S NEEDS AS IT LEVERAGES NEW TYPES OF DATA SOURCES. IT GETS USERS UP AND RUNNING WITH A PRODUCTION-READY, REAL-TIME API IN MINUTES, SAVING WEEKS OR MONTHS OF DEVELOPMENT TIME. “THE DEVELOPER EXPERIENCE GAP FOR DATA-DRIVEN APPS CONTINUES TO WIDEN AS ENTERPRISES ARE FACED WITH INTEGRATING AN EVER-GROWING NUMBER OF DATA SOURCES,” SAID JAMES GOVERNOR, CO-FOUNDER OF REDMONK. “HASURA IS DESIGNED TO ADDRESS THIS GAP BY ENABLING ENGINEERING TEAMS TO GET UP AND RUNNING WITH THE LATEST CLOUD-HOSTED, CUSTOM AND LEGACY DATA SOURCES TO BUILD NEW APIS AND APPS QUICKLY.” ADDITIONAL ANNOUNCEMENTS BY HASURA TODAY INCLUDE: HASURA CLOUD ENTERPRISE AVAILABILITY IN AWS MARKETPLACE, A DIGITAL CATALOG OF SOFTWARE LISTINGS THAT MAKES IT EASY TO FIND, TEST, BUY AND DEPLOY SOFTWARE THAT RUNS ON AMAZON WEB SERVICES (AWS), MAKES HASURA MORE BROADLY AND EASILY AVAILABLE TO USERS WORLDWIDE. AWS MARKETPLACE IS THE FIRST CLOUD MARKETPLACE IN WHICH HASURA IS AVAILABLE. THE AVAILABILITY OF HASURA CLOUD ENTERPRISE IN AWS MARKETPLACE MAKES IT EASIER FOR CUSTOMERS TO INCREASE THE SPEED OF DEVELOPMENT FOR THEIR OWN PRODUCTS THROUGH GRAPHQL DATA APIS. GENERAL AVAILABILITY OF HASURA ON GOOGLE CLOUD LETS HASURA CLOUD AND CLOUD ENTERPRISE USERS WITH DATABASES AND OTHER SERVICES ON GOOGLE CLOUD CREATE HASURA PROJECTS ON GOOGLE CLOUD, REDUCING EGRESS CHARGES AND IMPROVING PERFORMANCE DUE TO CO-LOCATION. HASURA CUSTOMERS USING VIRTUAL PRIVATE CLOUD (VPC) ON GOOGLE CLOUD ARE NOW ABLE TO PEER WITH THEIR OWN VPCS, ENABLING THEIR WORKLOADS TO COMMUNICATE INTERNALLY. THIS INCREASES SECURITY AS USER TRAFFIC REMAINS IN THE GOOGLE CLOUD NETWORK, NEVER TRAVERSING THE PUBLIC INTERNET. STREAMING SUBSCRIPTIONS API ALLOWS USERS TO BUILD HIGH-PERFORMANCE REAL-TIME APPS USING HASURA, STREAMING DATA TO THEIR CLIENTS IN BATCHES AND UPDATING DATA IN REAL-TIME. THIS EXPANDS ON HASURA’S PREVIOUS REAL-TIME API, WHICH IS BUILT WITH A LIVE-QUERY INTERFACE. MS SQL SERVER EVENT TRIGGERS SUPPORT ENABLES USERS TO CONNECT BUSINESS LOGIC APIS WITH HASURA TO INTEGRATE ASYNCHRONOUS BACKEND LOGIC INTO THEIR APPLICATIONS BY CALLING WEBHOOKS ON TABLE EVENTS SUCH AS INSERT/UPDATE/DELETE FOR SQL SERVER DATA SOURCES. THIS EXPANDS ON PREVIOUS SUPPORT FOR POSTGRES AND ENABLES USERS TO CONNECT BUSINESS LOGIC APIS WITH HASURA TO INTEGRATE ASYNCHRONOUS BACKEND LOGIC INTO THEIR APPLICATIONS. GITHUB INTEGRATION GENERAL AVAILABILITY INCREASES EASE OF CI/CD PIPELINE MANAGEMENT, RELIABILITY AND DEVELOPMENT SPEED BY HELPING DEVELOPERS MOVE QUICKLY AND EASILY BETWEEN LOCAL DEVELOPMENT AND HASURA CLOUD. A PREVIEW APPS FEATURE (IN BETA) ENABLES USERS TO QUICKLY TEST CHANGES TO METADATA MIGRATIONS AND LINK TO GITHUB PRS TO AUTOMATICALLY DEPLOY WITH EVERY PUSH. SUPPORT FOR OPENTELEMETRY TRACES IN HASURA CLOUD AND HASURA ENTERPRISE EDITIONS GIVES CUSTOMERS ENHANCED OBSERVABILITY THROUGH TRACES IN THE OPENTELEMETRY FORMAT VIA OPENTELEMETRY COMPATIBLE AGENTS AND DIRECT CONNECTIONS WITH APM TOOLS SUCH AS NEW RELIC AND DYNATRACE. THIS ENABLES THEM TO PROVIDE BETTER RELIABILITY AND END USER EXPERIENCES FOR THEIR MISSION-CRITICAL APPLICATIONS THROUGH RAPID PROBLEM DIAGNOSIS. “WE SEE THE INEVITABILITY OF DATA CONTINUING TO EXPLODE ACROSS THREE FRONTS – THE VOLUME OF DATA, THE TYPE OF DATA AND THE THINGS WE’RE DOING WITH THE DATA, INCLUDING TRANSACTIONAL, ANALYTICAL AND ML/AI,” SAID GOPAL. “OUR MISSION IS TO BE YOUR INFRASTRUCTURE PARTNER AS YOU’RE THINKING ABOUT HOW TO MAKE YOUR ORGANIZATION’S DATA AVAILABLE AND AS YOU’RE DESIGNING A STACK TO SUPPORT NEXT-GEN PRODUCT DEVELOPMENT AND MODERNIZATION. WE DO THIS BY HELPING YOU ACTIVATE THE DATA YOU ALREADY HAVE AND BY ENSURING THAT WE’RE CONTINUOUSLY EVOLVING TO SUPPORT THE RAPID EXPLOSION OF USE-CASES. THE INNOVATIONS ANNOUNCED TODAY ARE A KEY STEP TOWARD ACHIEVING THAT MISSION.” ABOUT HASURA HASURA IS HELPING TO BUILD THE MODERN WORLD OF GLOBALLY RELEVANT, DATA-DRIVEN APPLICATIONS AND APIS. HASURA’S RANGE OF DATA ACCESS SOLUTIONS HELPS ORGANIZATIONS ACCELERATE PRODUCT DELIVERY BY INSTANTLY CONNECTING DATA AND SERVICES TO APPLICATIONS WITH GRAPHQL APIS. FOR MORE INFORMATION, GO TO: HTTPS://HASURA.IO OR FOLLOW @HASURAHQ ON TWITTER.
- Genentech to Present Data From One of the Most Comprehensive Oncology Portfolios at the 2021 ASCO Annual Meeting Showcasing Advancements for People Living With Cancer
May 11, 2021 · businesswire.com
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new data from clinical trials of 19 approved and investigational medicines across 20 cancer types will be presented at the 2021 ASCO Annual Meeting, which will be held June 4-8, 2021. A total of 132 abstracts that include a Genentech medicine will be presented at this year's meeting. These data advance oncology by showing the importance of making patient-centric treatment decisions and providing tailored medical care based on specific cancer types. “We will be presenting data from across our diverse oncology portfolio that has the potential to help more people living with many types of cancers,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. “We are particularly excited about our compelling immunotherapy data in lung cancer, which may provide new hope for patients with earlier stage disease.” Focusing on earlier treatment and targeted lung cancer care Positive results from the Phase III IMpower010 study will be presented that show Tecentriq® (atezolizumab) improved disease-free survival (DFS) in people with resected early-stage non-small cell lung cancer (NSCLC) compared to best supportive care - a first in cancer immunotherapy. This advance is significant, as half of all people with early-stage lung cancer today still experience a recurrence following surgery; therefore, treating lung cancer early, before it has spread, can provide the best opportunity for a cure. Additionally, updated data for GavretoTM (pralsetinib) in patients with advanced RET fusion-positive NSCLC, including in patients who are treatment naïve, will be reported. These data highlight the need for early RET fusion-positive testing to identify candidates who may benefit from treatment with Gavreto. Exploring personalized cancer care for more patients Genentech will present several studies that take tumor-agnostic approaches to clinical development, and in breast cancer, that may benefit people with rare and common tumors alike. These studies bring together next-generation sequencing, targeted therapies and patient-centric clinical trial design that show how personalized treatment plans are helping to evolve the way people are treated. The Phase II ALPHA-T study, made possible through a collaboration with Foundation Medicine and Science37, is pioneering a decentralized approach to clinical trial design which enables patients to participate from their own homes while remaining under the care of their oncologist. The Phase II TAPISTRY study, a platform umbrella trial, will pair patients with immunotherapy, targeted therapy or treatment combinations based on distinct tumor biology characteristics. The similarly designed Phase II MyTACTIC study is enrolling a diverse population of patients to direct them to appropriately targeted treatments based on the results of comprehensive genomic profiling. With our research we are contributing to the body of evidence in hormone receptor (HR)-positive breast cancer, the most prevalent type of all breast cancers. For giredestrant, a third-generation oral selective estrogen receptor degrader (SERD), we will present data further supporting the tolerable safety profile and single agent clinical activity, as well as pharmacodynamics data from studies in HR-positive early and metastatic breast cancer. Defining new solutions for patients with difficult-to-treat blood cancer New and updated data in non-Hodgkin lymphoma (NHL) will be shared, including data from the T-cell engaging CD20xCD3 bispecific antibody development program. Glofitamab and mosunetuzumab are both T-cell engaging CD20xCD3 bispecific antibodies that are being studied as single agents or in combination with other Genentech therapies. Together, they may offer a new immunotherapy-based approach to tackle a range of blood cancers. In addition, data exploring novel combinations with mosunetuzumab and Polivy® (polatuzumab vedotin), an antibody-drug conjugate, will also be featured. These data demonstrate how Genentech continues to seek new solutions for people living with a range of malignant blood disorders, where treatment options are still limited and both relapse and treatment resistance are common. Furthermore, Genentech’s data showcase a commitment to health equity through medicine delivery approaches that reduce treatment time and cost, trial designs that help remove barriers to clinical trial participation, pioneering cancer immunotherapy to improve outcomes for earlier disease stages, and a focus on inclusivity through developing tumor-specific therapies and therapy combinations based on the specific characteristics of each person’s disease. Keep up to date with ASCO news and updates by using the hashtag #ASCO21 and follow Genentech on Twitter via @Genentech and on LinkedIn. Overview of key presentations featuring Genentech medicines Medicine Abstract title Abstract number Lung cancer Alecensa Final OS analysis from the phase III j-alex study of alectinib (ALC) versus crizotinib (CRZ) in Japanese ALK-inhibitor naïve ALK-positive non-small cell lung cancer (ALK+ NSCLC). 9022 Gavreto Safety and efficacy of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer: Update from the ARROW trial. 9089 Tecentriq IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC). 8500 Tecentriq Artificial intelligence (AI)–powered pathologic response (PathR) assessment of resection specimens after neoadjuvant atezolizumab in patients with non-small cell lung cancer: Results from the LCMC3 study. 106 Tecentriq Pooled analyses of immune-related adverse events (irAEs) and efficacy from the phase 3 trials IMpower130, IMpower132, and IMpower150. 9002 Tecentriq CONTACT-01: A phase III, randomized study of atezolizumab plus cabozantinib versus docetaxel in patients with metastatic non-small cell lung cancer (mNSCLC) previously treated with PD-L1/PD-1 inhibitors and platinum-containing chemotherapy. TPS9134 Tecentriq Clinicogenomic real-world data analysis of patients (pts) with KRAS G12C-mutant advanced non-small cell lung cancer (aNSCLC) from the natural history cohort of the Blood First Assay Screening Trial (BFAST). 9023 Tecentriq Real-world treatment patterns in stages IA-IIIB non-small cell lung cancer. e20528 Blood cancer Gazyva Obinutuzumab short-duration infusion (SDI) in previously untreated advanced follicular lymphoma: Results from the end of induction analysis of the phase IV GAZELLE study. 7545 Glofitamab Glofitamab step-up dosing (SUD): Complete response rates in updated efficacy data in heavily pretreated relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) patients (pts). 7519 Mosunetuzumab Promising tolerability and efficacy results from dose-escalation in an ongoing phase Ib/II study of mosunetuzumab (M) with polatuzumab vedotin (Pola) in patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin’s lymphoma (B-NHL). 7520 Polivy Polatuzumab vedotin (Pola) + rituximab (R) + lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Primary analysis of a phase 1b/2 trial. 7512 Venclexta Measurable residual disease response in acute myeloid leukemia treated with venetoclax and azacitidine. 7018 Breast cancer Giredestrant acelERA Breast Cancer (BC): Phase II study evaluating efficacy and safety of giredestrant (GDC-9545) versus physician’s choice of endocrine monotherapy in patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2-) locally advanced or metastatic breast cancer (LA/mBC). TPS1100 Giredestrant persevERA Breast Cancer (BC): Phase III study evaluating the efficacy and safety of giredestrant (GDC-9545) + palbociclib versus letrozole + palbociclib in patients (pts) with estrogen-receptor-positive, HER2-negative locally advanced or metastatic BC (ER+/HER2– LA/mBC). TPS1103 Giredestrant Safety and activity of single-agent giredestrant (GDC-9545) from a phase Ia/b study in patients (pts) with estrogen receptor-positive (ER+), HER2-negative locally advanced/metastatic breast cancer (LA/mBC). 1017 Giredestrant Evaluation of pharmacodynamic (PD) and biologic activity in a preoperative window-of-opportunity (WOO) study of giredestrant (GDC-9545) in postmenopausal patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2–) operable breast cancer (BC). 577 Kadcyla Safety of trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive locally advanced or metastatic breast cancer (mBC): Final results from KAMILLA Cohorts 1 (global) and 2 (Asia). 1039 Phesgo Potential non-drug cost differences associated with the use of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in the treatment of HER2-positive early breast cancer patients in Western Europe and the United States. 544 Tecentriq The tumor microenvironment (TME) and atezolizumab + nab-paclitaxel (A+nP) activity in metastatic triple-negative breast cancer (mTNBC): IMpassion130. 1006 Colon cancer Tecentriq Phase Ib/II open-label, randomized evaluation of atezolizumab (atezo) + Imprime PGG (Imprime) + bevacizumab (bev) vs regorafenib (rego) in MORPHEUS: Microsatellite-stable (MSS) metastatic colorectal cancer (mCRC). 3559 Liver cancer Tecentriq IMbrave150: Exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor). 4071 Tecentriq IMbrave150: Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with main trunk and/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in a global Ph III study. 4073 Personalized healthcare and health equity Association of electronic-health record (EHR)-derived race with BRCA testing in patients (pts) with breast cancer (BC) with similar genetic ancestry (GA) in a clinicogenomic database (CGDB). 6524 Racial, ethnic, and socioeconomic disparities in treatment outcomes in patients (pts) with diffuse large B-cell lymphoma (DLBCL): A U.S. real-world study using a de-identified electronic health record (EHR)-derived database. e18514 Tumor agnostic Alecensa Alpha-T: An innovative decentralized (home-based) phase 2 trial of alectinib in ALK-positive (ALK+) solid tumors in a histology-agnostic setting. TPS3155 Gavreto Clinical activity and safety of the RET inhibitor pralsetinib in patients with RET fusion-positive solid tumors: Update from the ARROW trial. 3079 Rozlytrek, Alecensa, Tecentriq, Ipatasertib, Kadcyla, Inavolisib Tumor-agnostic precision immuno-oncology and somatic targeting rationale for you (TAPISTRY): a novel platform umbrella trial. TPS3154 Rozlytrek, Inavolisib, Ipatasertib, Tecentriq, Kadcyla, Perjeta, Herceptin A study evaluating targeted therapies in participants who have advanced solid tumors with genomic alterations or protein expression patterns predictive of response (MyTACTIC). TPS1588 About Gavreto Gavreto is a once-daily, oral precision therapy designed to selectively target RET alterations, including fusions and mutations, regardless of the tissue of origin. Preclinical data have shown that Gavreto inhibits primary RET fusions and mutations that cause cancer in subsets of patients, as well as secondary RET mutations predicted to drive resistance to treatment. Blueprint Medicines and Genentech are co-developing Gavreto for the treatment of patients with various types of RET-altered cancers. Gavreto™ U.S. Indications Gavreto™ is a prescription medicine used to treat certain cancers caused by abnormal rearranged during transfection (RET) gene in: adults with non-small cell lung cancer (NSCLC) that has spread adults and children 12 years of age and older with advanced medullary thyroid cancer (MTC) or MTC that has spread who require a medicine by mouth or injection (systemic therapy) adults and children 12 years of age and older with advanced thyroid cancer or thyroid cancer that has spread who require a medicine by mouth or injection (systemic therapy) and who have received radioactive iodine and it did not work or is no longer working A patient’s healthcare provider will perform a test to make sure that Gavreto is right for them. Gavreto was approved based on the percentage of patients whose tumor size shrank or disappeared after treatment and how long that response lasted. There are ongoing studies to confirm the benefit of Gavreto. Important Safety Information Gavreto may cause serious side effects, including Lung Problems: Gavreto may cause severe or life-threatening inflammation of the lungs during treatment, that can lead to death. Patients should tell their healthcare provider right away if they have any new or worsening symptoms, including shortness of breath, cough, or fever. High blood pressure (hypertension): High blood pressure is common with Gavreto and may sometimes be severe. Patients should check their blood pressure regularly during treatment with Gavreto. Patients should tell their healthcare provider if they have increased blood pressure readings or get any symptoms of high blood pressure, including confusion, dizziness, headaches, chest pain or shortness of breath. Liver problems: Liver problems (increased liver function blood test results) can happen during treatment with Gavreto and may sometimes be serious. A healthcare provider will do blood tests before and during treatment with Gavreto to check patients for liver problems. Patients should tell their healthcare provider right away if they get any signs or symptoms of liver problem during treatment, including yellowing of their skin or the white part of their eyes (jaundice), loss of appetite, nausea or vomiting, dark “tea-colored” urine, pain on the upper right side of their stomach area, sleepiness, bleeding or bruising. Bleeding problems: Gavreto can cause bleeding which can be serious and cause death. Patients should tell their healthcare provider if they have any signs or symptoms of bleeding during treatment, including vomiting blood or if their vomit looks like coffee-grounds, unusual vaginal bleeding, nose bleeds that happen often, pink or brown urine, drowsiness or difficulty being awakened, red or black (looks like tar) stools, confusion, coughing up blood or blood clots, headache, unusual bleeding or bruising of their skin, change in speech, or menstrual bleeding that is heavier than normal. Tumor lysis syndrome (TLS): TLS is caused by a fast breakdown of cancer cells. TLS can cause patients to have kidney failure and the need for dialysis treatment, an abnormal heartbeat, and may sometimes lead to hospitalization. A healthcare provider may do blood tests to check patients for TLS. Patients should stay well hydrated during treatment with Gavreto. Patients should call their healthcare provider or get emergency medical help right away if they develop any of these symptoms during treatment with Gavreto: nausea, shortness of breath, vomiting, muscle cramps, weakness, seizures or swelling. Risk of wound healing problems: Wounds may not heal properly during treatment with Gavreto. Patients should tell their healthcare provider if they plan to have any surgery before or during treatment with Gavreto. Patients should not take Gavreto for at least 5 days before surgery. A healthcare provider should tell patients when they may start taking Gavreto again after surgery. Before taking Gavreto, patients should tell their healthcare provider about all of their medical conditions, including if they: have lung or breathing problems other than lung cancer have high blood pressure have bleeding problems plan to have surgery are pregnant or plan to become pregnant. Gavreto can harm an unborn baby. Females who are able to become pregnant: A healthcare provider will do a pregnancy test before patients start Gavreto. Should use an effective form of non-hormonal birth control (contraception) during treatment with Gavreto and for 2 weeks after the final dose of Gavreto. Birth control methods that contain hormones (such as birth control pills, injections or transdermal system patches) may not work as well during treatment with Gavreto. Patients should talk to their healthcare provider about birth control methods that may be right for them during this time. Patients should tell their healthcare provider right away if they become pregnant or think they might be pregnant during treatment with Gavreto. Males with female partners who are able to become pregnant should use effective birth control (contraception) during treatment and for 1 week after their final dose of Gavreto. are breastfeeding or plan to breastfeed. It is not known if Gavreto passes into breast milk. Patients should not breastfeed during treatment and for 1 week after their last dose of Gavreto. Patients should tell their healthcare provider about all the medicines they take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Gavreto may affect the way other medicines work, and other medicines may affect how Gavreto works. The most common side effects of Gavreto include: constipation, decreased levels of phosphate in the blood, high blood pressure, decreased levels of calcium in the blood, tiredness, decreased levels of body salt (sodium) in the blood, muscle and joint pain, diarrhea, abnormal liver function blood tests, and decreased white blood cell, red blood cell, and platelet counts. Gavreto may affect fertility in males and females, which may affect a patient’s ability to have children. Patients should talk to their healthcare provider if this is a concern for them. These are not all of the possible side effects of Gavreto. Patients should call their doctor for medical advice about side effects. Patients are encouraged to report side effects to the FDA. Visit FDA MedWatch or call 1-800-FDA-1088. Please see the full Prescribing Information and Patient Information for Gavreto. Blueprint Medicines, Gavreto, YourBlueprint and associated logos are trademarks of Blueprint Medicines Corporation. About Polivy™ (polatuzumab vedotin-piiq) Polivy is a first-in-class anti-CD79b antibody-drug conjugate (ADC). The CD79b protein is expressed specifically in the majority of B-cells, an immune cell impacted in some types of non-Hodgkin’s lymphoma (NHL), making it a promising target for the development of new therapies. Polivy binds to CD79b and destroys these B-cells through the delivery of an anti-cancer agent, which is thought to minimize the effects on normal cells. Polivy is being developed by Roche using Seattle Genetics ADC technology and is currently being investigated for the treatment of several types of NHL. Polivy U.S. Indication Polivy is a prescription medicine used with other medicines, bendamustine and a rituximab product, to treat diffuse large B-cell lymphoma in adults who have progressed after at least two prior therapies. The accelerated approval of Polivy is based on a type of response rate. There are ongoing studies to confirm the clinical benefit of Polivy. Important Safety Information Possible serious side effects Everyone reacts differently to Polivy therapy, so it’s important to know what the side effects are. Some people who have been treated with Polivy have experienced serious to fatal side effects. A patient’s doctor may stop or adjust a patient’s treatment if any serious side effects occur. Patients must contact their healthcare team if there are any signs of these side effects. Nerve problems in arms and legs: This may happen as early as after the first dose and may worsen with every dose. If a patient already has nerve pain, Polivy may make it worse. The patient’s doctor will monitor for signs and symptoms, such as changes in sense of touch, numbness or tingling in hands or feet, nerve pain, burning sensation, any muscle weakness, or changes to walking patterns Infusion-related reactions: A patient may experience fever, chills, rash, breathing problems, low blood pressure, or hives within 24 hours of the infusion Infections: Patients should contact their healthcare team, if they experience a fever of 100.4°F or higher, chills, cough, or pain during urination. Also, a patient’s doctor may give medication before giving Polivy, which may prevent some infections, and monitor blood counts throughout treatment with Polivy. Treatment with POLIVY can cause severe low blood cell counts Rare and serious brain infections: A patient’s doctor will monitor the patient closely for signs and symptoms of these types of infections. Patients should contact their doctor if they experience confusion, dizziness or loss of balance, trouble talking or walking, or vision changes Tumor lysis syndrome: Caused by the fast breakdown of cancer cells. Signs include nausea, vomiting, diarrhea, and lack of energy Potential harm to liver: Some signs include tiredness, weight loss, pain in the abdomen, dark urine, and yellowing of the skin or the white part of the eyes. Patients may be at higher risk if they already have liver problems or are taking other medication Side effects seen most often The most common side effects during treatment were Low blood cell counts (platelets, red blood cells, white blood cells) Nerve problems in arms and legs Tiredness or lack of energy Diarrhea Nausea Fever Decreased appetite Infections Polivy may not be for everyone. A patient should talk to their doctor if they are Pregnant or may be pregnant: Data have shown that Polivy may harm an unborn baby Planning to become pregnant: Women should avoid getting pregnant while taking Polivy. Women should use effective contraception during treatment and for at least 3 months after their last Polivy treatment. Men taking Polivy should use effective contraception during treatment and for at least 5 months after their last Polivy treatment Breastfeeding: Women should not breastfeed while taking Polivy and for at least 2 months after the last dose These may not be all the side effects. Patients should talk to their healthcare provider for more information about the benefits and risks of Polivy treatment. Report side effects to the FDA at (800) FDA-1088 or http://www.fda.gov/medwatch. Report side effects to Genentech at (888) 835-2555. Please visit http://www.Polivy.com for the full Prescribing Information for additional Important Safety Information. About Tecentriq (atezolizumab) Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1. Tecentriq is designed to bind to PD-L1 expressed on tumor cells and tumor-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, Tecentriq may enable the re-activation of T cells. Tecentriq may also affect normal cells. Tecentriq U.S. Indications Tecentriq is a prescription medicine used to treat adults with: A type of lung cancer called non-small cell lung cancer (NSCLC). Tecentriq may be used alone as the first treatment in patients with lung cancer if: Their cancer has spread or grown, and Their cancer tests positive for “high PD-L1”, and Their tumor does not have an abnormal “EGFR” or “ALK” gene. Tecentriq may be used with the medicines bevacizumab, paclitaxel, and carboplatin as the first treatment in patients with lung cancer if: Their cancer has spread or grown and Is a type of lung cancer called “non-squamous NSCLC”, and Their tumor does not have an abnormal “EGFR” or “ALK” gene. Tecentriq may be used with the medicines paclitaxel protein-bound and carboplatin as the first treatment in patients with lung cancer if: Their cancer has spread or grown, and Is a type of lung cancer called “non-squamous NSCLC”, and Their tumor does not have an abnormal “EGFR” or “ALK” gene. Tecentriq may be used alone in patients with lung cancer if: Their cancer has spread or grown, and They have tried chemotherapy that contains platinum, and it did not work or is no longer working. If a patient’s tumor has an abnormal “EGFR” or “ALK” gene, they should have also tried an FDA-approved therapy for tumors with these abnormal genes, and it did not work or is no longer working. A type of breast cancer called triple-negative breast cancer (TNBC). Tecentriq may be used with the medicine paclitaxel protein-bound in patients with TNBC when their breast cancer: Has spread or cannot be removed by surgery. And Their cancer tests positive for “PD-L1”. The approval of Tecentriq in these patients is based on a study that measured the amount of time until patients’ disease worsened. Continued approval for this use may depend on the results of an ongoing study to confirm benefit. Tecentriq is not for use with the medicine paclitaxel (a different medicine than paclitaxel protein-bound) in patients with TNBC when their breast cancer has spread or cannot be removed by surgery. A type of liver cancer called hepatocellular carcinoma (HCC). Tecentriq may be used with the medicine bevacizumab in patients with HCC if: Their cancer has spread or cannot be removed by surgery, and They have not received other medicines by mouth or injection through their vein (IV) to treat their cancer. It is not known if Tecentriq is safe and effective in children. Important Safety Information The most important information about Tecentriq is: Tecentriq can cause the immune system to attack normal organs and tissues and can affect the way they work. These problems can sometimes become serious or life-threatening and can lead to death. Patients can have more than one of these problems at the same time. These problems may happen anytime during treatment or even after treatment has ended. Patients should call or see their healthcare provider right away if they develop any new or worse signs of symptoms, including: Lung problems Cough Shortness of breath Chest pain Intestinal problems Diarrhea (loose stools) or more bowel movements than usual Stools that are black, tarry, sticky, or have blood or mucus Severe stomach area (abdomen) pain or tenderness Liver problems Yellowing of the skin or the whites of the eyes Severe nausea or vomiting Pain on the right side of the stomach area (abdomen) Dark urine (tea-colored) Bleeding or bruising more easily than normal and feeling less hungry than usual Hormone gland problems Headaches that will not go away or unusual headaches Eye sensitivity to light Eye problems Rapid heartbeat Increased sweating Extreme tiredness Weight gain or weight loss Changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness Feeling more hungry or thirsty than usual Urinating more often than usual Hair loss Feeling cold Constipation The voice gets deeper Dizziness or fainting Kidney problems Decrease in the amount of urine Blood in the urine Swelling of ankles Loss of appetite Skin problems Rash Itching Skin blistering or peeling Painful sores or ulcers in mouth or nose, throat, or genital area Fever or flu-like symptoms Swollen lymph nodes Problems can also happen in other organs. These are not all of the signs and symptoms of immune system problems that can happen with Tecentriq. Patients should call or see their healthcare provider right away for any new or worse signs or symptoms, including: Chest pain, irregular heartbeat, shortness of breath, or swelling of ankles Confusion, sleepiness, memory problems, changes in mood or behavior, stiff neck, balance problems, tingling or numbness of the arms or legs Double vision, blurry vision, sensitivity to light, eye pain, changes in eyesight Persistent or severe muscle pain or weakness, muscle cramps Low red blood cells, bruising Infusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include: Chills or shaking Itching or rash Flushing Shortness of breath or wheezing Dizziness Feeling like passing out Fever Back or neck pain Complications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be serious and can lead to death. These complications may happen if a patient underwent transplantation either before or after being treated with Tecentriq. A patient’s healthcare provider will monitor them for these complications. Getting medical treatment right away may help keep these problems from becoming more serious. A healthcare provider will check patients for these problems during their treatment with Tecentriq. A healthcare provider may treat patients with corticosteroid or hormone replacement medicines. A healthcare provider may also need to delay or completely stop treatment with Tecentriq if patients have severe side effects. Before receiving Tecentriq, patients should tell their healthcare provider about all of their medical conditions, including if they: Have immune system problems such as Crohn’s disease, ulcerative colitis, or lupus Have had an organ transplant Have received or plan to receive a stem cell transplant that uses donor stem cells (allogeneic) Have received radiation treatment to their chest area Have a condition that affects the nervous system (such as myasthenia gravis or Guillain-Barre syndrome Are pregnant or plan to become pregnant. Tecentriq can harm an unborn baby. Patients should tell their healthcare provider right away if they become pregnant or think they may be pregnant during treatment with Tecentriq. Females who are able to become pregnant: Should have a healthcare provider do a pregnancy test before they start treatment with Tecentriq. Should use an effective method of birth control during their treatment and for at least 5 months after the last dose of Tecentriq. Should have a healthcare provider do a pregnancy test before they start treatment with Tecentriq. Should use an effective method of birth control during their treatment and for at least 5 months after the last dose of Tecentriq. Are breastfeeding or plan to breastfeed. It is not known if Tecentriq passes into breast milk. Patients should not breastfeed during treatment and for at least 5 months after the last dose of Tecentriq. Patients should tell their healthcare provider about all the medicines they take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. The most common side effects of Tecentriq when used alone include: Feeling tired or weak Nausea Cough Shortness of breath Decreased appetite The most common side effects of Tecentriq when used in lung cancer with other anti-cancer medicines include: Feeling tired or weak Nausea Hair loss Constipation Diarrhea Decreased appetite The most common side effects of Tecentriq when used in TNBC with paclitaxel protein-bound include: Decrease in hemoglobin (anemia) Decreased white blood cells Hair loss Tingling or numbness in hands and feet Feeling tired Nausea Diarrhea Constipation Cough Headache Vomiting Decreased appetite The most common side effects of Tecentriq when used in hepatocellular carcinoma (HCC) with bevacizumab include: High blood pressure Feeling tired or weak Too much protein in the urine Tecentriq may cause fertility problems in females, which may affect their ability to have children. Patients should talk to their healthcare provider if they have concerns about fertility. These are not all the possible side effects of Tecentriq. Patients should ask their healthcare provider or pharmacist for more information about the benefits and side effects of Tecentriq. Report side effects to the FDA at (800) FDA-1088 or http://www.fda.gov/medwatch. Report side effects to Genentech at (888) 835-2555. Please visit http://www.Tecentriq.com for the full Tecentriq Prescribing Information and Medication Guide for additional Important Safety Information. Blueprint Medicines and Roche are co-developing Gavreto (pralsetinib) globally, excluding Greater China.* Blueprint Medicines and Genentech, a wholly-owned member of the Roche Group, are commercializing Gavreto in the US and Roche has exclusive commercialization rights for Gavreto outside of the US, excluding Greater China.* *Greater China encompasses Mainland China, Hong Kong, Macau and Taiwan. CStone Pharmaceuticals retains all rights to the development and commercialization of Gavreto in Greater China under its existing collaboration with Blueprint Medicines. All trademarks used or mentioned in this release are protected by law. Blueprint Medicines, Gavreto and associated logos are trademarks of Blueprint Medicines Corporation. About Genentech Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.
- GENENTECH TO PRESENT DATA FROM ONE OF THE MOST COMPREHENSIVE ONCOLOGY PORTFOLIOS AT THE 2021 ASCO ANNUAL MEETING SHOWCASING ADVANCEMENTS FOR PEOPLE LIVING WITH CANCER
May 11, 2021
SOUTH SAN FRANCISCO, CALIF.--(BUSINESS WIRE)--GENENTECH, A MEMBER OF THE ROCHE GROUP (SIX: RO, ROG; OTCQX: RHHBY), TODAY ANNOUNCED THAT NEW DATA FROM CLINICAL TRIALS OF 19 APPROVED AND INVESTIGATIONAL MEDICINES ACROSS 20 CANCER TYPES WILL BE PRESENTED AT THE 2021 ASCO ANNUAL MEETING, WHICH WILL BE HELD JUNE 4-8, 2021. A TOTAL OF 132 ABSTRACTS THAT INCLUDE A GENENTECH MEDICINE WILL BE PRESENTED AT THIS YEAR'S MEETING. THESE DATA ADVANCE ONCOLOGY BY SHOWING THE IMPORTANCE OF MAKING PATIENT-CENTRIC TREATMENT DECISIONS AND PROVIDING TAILORED MEDICAL CARE BASED ON SPECIFIC CANCER TYPES. “WE WILL BE PRESENTING DATA FROM ACROSS OUR DIVERSE ONCOLOGY PORTFOLIO THAT HAS THE POTENTIAL TO HELP MORE PEOPLE LIVING WITH MANY TYPES OF CANCERS,” SAID LEVI GARRAWAY, M.D., PH.D., CHIEF MEDICAL OFFICER AND HEAD OF GLOBAL PRODUCT DEVELOPMENT. “WE ARE PARTICULARLY EXCITED ABOUT OUR COMPELLING IMMUNOTHERAPY DATA IN LUNG CANCER, WHICH MAY PROVIDE NEW HOPE FOR PATIENTS WITH EARLIER STAGE DISEASE.” FOCUSING ON EARLIER TREATMENT AND TARGETED LUNG CANCER CARE POSITIVE RESULTS FROM THE PHASE III IMPOWER010 STUDY WILL BE PRESENTED THAT SHOW TECENTRIQ® (ATEZOLIZUMAB) IMPROVED DISEASE-FREE SURVIVAL (DFS) IN PEOPLE WITH RESECTED EARLY-STAGE NON-SMALL CELL LUNG CANCER (NSCLC) COMPARED TO BEST SUPPORTIVE CARE - A FIRST IN CANCER IMMUNOTHERAPY. THIS ADVANCE IS SIGNIFICANT, AS HALF OF ALL PEOPLE WITH EARLY-STAGE LUNG CANCER TODAY STILL EXPERIENCE A RECURRENCE FOLLOWING SURGERY; THEREFORE, TREATING LUNG CANCER EARLY, BEFORE IT HAS SPREAD, CAN PROVIDE THE BEST OPPORTUNITY FOR A CURE. ADDITIONALLY, UPDATED DATA FOR GAVRETOTM (PRALSETINIB) IN PATIENTS WITH ADVANCED RET FUSION-POSITIVE NSCLC, INCLUDING IN PATIENTS WHO ARE TREATMENT NAÏVE, WILL BE REPORTED. THESE DATA HIGHLIGHT THE NEED FOR EARLY RET FUSION-POSITIVE TESTING TO IDENTIFY CANDIDATES WHO MAY BENEFIT FROM TREATMENT WITH GAVRETO. EXPLORING PERSONALIZED CANCER CARE FOR MORE PATIENTS GENENTECH WILL PRESENT SEVERAL STUDIES THAT TAKE TUMOR-AGNOSTIC APPROACHES TO CLINICAL DEVELOPMENT, AND IN BREAST CANCER, THAT MAY BENEFIT PEOPLE WITH RARE AND COMMON TUMORS ALIKE. THESE STUDIES BRING TOGETHER NEXT-GENERATION SEQUENCING, TARGETED THERAPIES AND PATIENT-CENTRIC CLINICAL TRIAL DESIGN THAT SHOW HOW PERSONALIZED TREATMENT PLANS ARE HELPING TO EVOLVE THE WAY PEOPLE ARE TREATED. THE PHASE II ALPHA-T STUDY, MADE POSSIBLE THROUGH A COLLABORATION WITH FOUNDATION MEDICINE AND SCIENCE37, IS PIONEERING A DECENTRALIZED APPROACH TO CLINICAL TRIAL DESIGN WHICH ENABLES PATIENTS TO PARTICIPATE FROM THEIR OWN HOMES WHILE REMAINING UNDER THE CARE OF THEIR ONCOLOGIST. THE PHASE II TAPISTRY STUDY, A PLATFORM UMBRELLA TRIAL, WILL PAIR PATIENTS WITH IMMUNOTHERAPY, TARGETED THERAPY OR TREATMENT COMBINATIONS BASED ON DISTINCT TUMOR BIOLOGY CHARACTERISTICS. THE SIMILARLY DESIGNED PHASE II MYTACTIC STUDY IS ENROLLING A DIVERSE POPULATION OF PATIENTS TO DIRECT THEM TO APPROPRIATELY TARGETED TREATMENTS BASED ON THE RESULTS OF COMPREHENSIVE GENOMIC PROFILING. WITH OUR RESEARCH WE ARE CONTRIBUTING TO THE BODY OF EVIDENCE IN HORMONE RECEPTOR (HR)-POSITIVE BREAST CANCER, THE MOST PREVALENT TYPE OF ALL BREAST CANCERS. FOR GIREDESTRANT, A THIRD-GENERATION ORAL SELECTIVE ESTROGEN RECEPTOR DEGRADER (SERD), WE WILL PRESENT DATA FURTHER SUPPORTING THE TOLERABLE SAFETY PROFILE AND SINGLE AGENT CLINICAL ACTIVITY, AS WELL AS PHARMACODYNAMICS DATA FROM STUDIES IN HR-POSITIVE EARLY AND METASTATIC BREAST CANCER. DEFINING NEW SOLUTIONS FOR PATIENTS WITH DIFFICULT-TO-TREAT BLOOD CANCER NEW AND UPDATED DATA IN NON-HODGKIN LYMPHOMA (NHL) WILL BE SHARED, INCLUDING DATA FROM THE T-CELL ENGAGING CD20XCD3 BISPECIFIC ANTIBODY DEVELOPMENT PROGRAM. GLOFITAMAB AND MOSUNETUZUMAB ARE BOTH T-CELL ENGAGING CD20XCD3 BISPECIFIC ANTIBODIES THAT ARE BEING STUDIED AS SINGLE AGENTS OR IN COMBINATION WITH OTHER GENENTECH THERAPIES. TOGETHER, THEY MAY OFFER A NEW IMMUNOTHERAPY-BASED APPROACH TO TACKLE A RANGE OF BLOOD CANCERS. IN ADDITION, DATA EXPLORING NOVEL COMBINATIONS WITH MOSUNETUZUMAB AND POLIVY® (POLATUZUMAB VEDOTIN), AN ANTIBODY-DRUG CONJUGATE, WILL ALSO BE FEATURED. THESE DATA DEMONSTRATE HOW GENENTECH CONTINUES TO SEEK NEW SOLUTIONS FOR PEOPLE LIVING WITH A RANGE OF MALIGNANT BLOOD DISORDERS, WHERE TREATMENT OPTIONS ARE STILL LIMITED AND BOTH RELAPSE AND TREATMENT RESISTANCE ARE COMMON. FURTHERMORE, GENENTECH’S DATA SHOWCASE A COMMITMENT TO HEALTH EQUITY THROUGH MEDICINE DELIVERY APPROACHES THAT REDUCE TREATMENT TIME AND COST, TRIAL DESIGNS THAT HELP REMOVE BARRIERS TO CLINICAL TRIAL PARTICIPATION, PIONEERING CANCER IMMUNOTHERAPY TO IMPROVE OUTCOMES FOR EARLIER DISEASE STAGES, AND A FOCUS ON INCLUSIVITY THROUGH DEVELOPING TUMOR-SPECIFIC THERAPIES AND THERAPY COMBINATIONS BASED ON THE SPECIFIC CHARACTERISTICS OF EACH PERSON’S DISEASE. KEEP UP TO DATE WITH ASCO NEWS AND UPDATES BY USING THE HASHTAG #ASCO21 AND FOLLOW GENENTECH ON TWITTER VIA @GENENTECH AND ON LINKEDIN. OVERVIEW OF KEY PRESENTATIONS FEATURING GENENTECH MEDICINES MEDICINE ABSTRACT TITLE ABSTRACT NUMBER LUNG CANCER ALECENSA FINAL OS ANALYSIS FROM THE PHASE III J-ALEX STUDY OF ALECTINIB (ALC) VERSUS CRIZOTINIB (CRZ) IN JAPANESE ALK-INHIBITOR NAÏVE ALK-POSITIVE NON-SMALL CELL LUNG CANCER (ALK+ NSCLC). 9022 GAVRETO SAFETY AND EFFICACY OF PRALSETINIB IN PATIENTS WITH ADVANCED RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER: UPDATE FROM THE ARROW TRIAL. 9089 TECENTRIQ IMPOWER010: PRIMARY RESULTS OF A PHASE III GLOBAL STUDY OF ATEZOLIZUMAB VERSUS BEST SUPPORTIVE CARE AFTER ADJUVANT CHEMOTHERAPY IN RESECTED STAGE IB-IIIA NON-SMALL CELL LUNG CANCER (NSCLC). 8500 TECENTRIQ ARTIFICIAL INTELLIGENCE (AI)–POWERED PATHOLOGIC RESPONSE (PATHR) ASSESSMENT OF RESECTION SPECIMENS AFTER NEOADJUVANT ATEZOLIZUMAB IN PATIENTS WITH NON-SMALL CELL LUNG CANCER: RESULTS FROM THE LCMC3 STUDY. 106 TECENTRIQ POOLED ANALYSES OF IMMUNE-RELATED ADVERSE EVENTS (IRAES) AND EFFICACY FROM THE PHASE 3 TRIALS IMPOWER130, IMPOWER132, AND IMPOWER150. 9002 TECENTRIQ CONTACT-01: A PHASE III, RANDOMIZED STUDY OF ATEZOLIZUMAB PLUS CABOZANTINIB VERSUS DOCETAXEL IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (MNSCLC) PREVIOUSLY TREATED WITH PD-L1/PD-1 INHIBITORS AND PLATINUM-CONTAINING CHEMOTHERAPY. TPS9134 TECENTRIQ CLINICOGENOMIC REAL-WORLD DATA ANALYSIS OF PATIENTS (PTS) WITH KRAS G12C-MUTANT ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC) FROM THE NATURAL HISTORY COHORT OF THE BLOOD FIRST ASSAY SCREENING TRIAL (BFAST). 9023 TECENTRIQ REAL-WORLD TREATMENT PATTERNS IN STAGES IA-IIIB NON-SMALL CELL LUNG CANCER. E20528 BLOOD CANCER GAZYVA OBINUTUZUMAB SHORT-DURATION INFUSION (SDI) IN PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA: RESULTS FROM THE END OF INDUCTION ANALYSIS OF THE PHASE IV GAZELLE STUDY. 7545 GLOFITAMAB GLOFITAMAB STEP-UP DOSING (SUD): COMPLETE RESPONSE RATES IN UPDATED EFFICACY DATA IN HEAVILY PRETREATED RELAPSED/REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL) PATIENTS (PTS). 7519 MOSUNETUZUMAB PROMISING TOLERABILITY AND EFFICACY RESULTS FROM DOSE-ESCALATION IN AN ONGOING PHASE IB/II STUDY OF MOSUNETUZUMAB (M) WITH POLATUZUMAB VEDOTIN (POLA) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) B-CELL NON-HODGKIN’S LYMPHOMA (B-NHL). 7520 POLIVY POLATUZUMAB VEDOTIN (POLA) + RITUXIMAB (R) + LENALIDOMIDE (LEN) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): PRIMARY ANALYSIS OF A PHASE 1B/2 TRIAL. 7512 VENCLEXTA MEASURABLE RESIDUAL DISEASE RESPONSE IN ACUTE MYELOID LEUKEMIA TREATED WITH VENETOCLAX AND AZACITIDINE. 7018 BREAST CANCER GIREDESTRANT ACELERA BREAST CANCER (BC): PHASE II STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT (GDC-9545) VERSUS PHYSICIAN’S CHOICE OF ENDOCRINE MONOTHERAPY IN PATIENTS (PTS) WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE (ER+/HER2-) LOCALLY ADVANCED OR METASTATIC BREAST CANCER (LA/MBC). TPS1100 GIREDESTRANT PERSEVERA BREAST CANCER (BC): PHASE III STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT (GDC-9545) + PALBOCICLIB VERSUS LETROZOLE + PALBOCICLIB IN PATIENTS (PTS) WITH ESTROGEN-RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BC (ER+/HER2– LA/MBC). TPS1103 GIREDESTRANT SAFETY AND ACTIVITY OF SINGLE-AGENT GIREDESTRANT (GDC-9545) FROM A PHASE IA/B STUDY IN PATIENTS (PTS) WITH ESTROGEN RECEPTOR-POSITIVE (ER+), HER2-NEGATIVE LOCALLY ADVANCED/METASTATIC BREAST CANCER (LA/MBC). 1017 GIREDESTRANT EVALUATION OF PHARMACODYNAMIC (PD) AND BIOLOGIC ACTIVITY IN A PREOPERATIVE WINDOW-OF-OPPORTUNITY (WOO) STUDY OF GIREDESTRANT (GDC-9545) IN POSTMENOPAUSAL PATIENTS (PTS) WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE (ER+/HER2–) OPERABLE BREAST CANCER (BC). 577 KADCYLA SAFETY OF TRASTUZUMAB EMTANSINE (T-DM1) IN PATIENTS (PTS) WITH HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (MBC): FINAL RESULTS FROM KAMILLA COHORTS 1 (GLOBAL) AND 2 (ASIA). 1039 PHESGO POTENTIAL NON-DRUG COST DIFFERENCES ASSOCIATED WITH THE USE OF THE FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB FOR SUBCUTANEOUS INJECTION (PH FDC SC) IN THE TREATMENT OF HER2-POSITIVE EARLY BREAST CANCER PATIENTS IN WESTERN EUROPE AND THE UNITED STATES. 544 TECENTRIQ THE TUMOR MICROENVIRONMENT (TME) AND ATEZOLIZUMAB + NAB-PACLITAXEL (A+NP) ACTIVITY IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER (MTNBC): IMPASSION130. 1006 COLON CANCER TECENTRIQ PHASE IB/II OPEN-LABEL, RANDOMIZED EVALUATION OF ATEZOLIZUMAB (ATEZO) + IMPRIME PGG (IMPRIME) + BEVACIZUMAB (BEV) VS REGORAFENIB (REGO) IN MORPHEUS: MICROSATELLITE-STABLE (MSS) METASTATIC COLORECTAL CANCER (MCRC). 3559 LIVER CANCER TECENTRIQ IMBRAVE150: EXPLORATORY ANALYSIS TO EXAMINE THE ASSOCIATION BETWEEN TREATMENT RESPONSE AND OVERALL SURVIVAL (OS) IN PATIENTS (PTS) WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) TREATED WITH ATEZOLIZUMAB (ATEZO) + BEVACIZUMAB (BEV) VERSUS SORAFENIB (SOR). 4071 TECENTRIQ IMBRAVE150: EXPLORATORY EFFICACY AND SAFETY RESULTS OF HEPATOCELLULAR CARCINOMA (HCC) PATIENTS (PTS) WITH MAIN TRUNK AND/OR CONTRALATERAL PORTAL VEIN INVASION (VP4) TREATED WITH ATEZOLIZUMAB (ATEZO) + BEVACIZUMAB (BEV) VERSUS SORAFENIB (SOR) IN A GLOBAL PH III STUDY. 4073 PERSONALIZED HEALTHCARE AND HEALTH EQUITY ASSOCIATION OF ELECTRONIC-HEALTH RECORD (EHR)-DERIVED RACE WITH BRCA TESTING IN PATIENTS (PTS) WITH BREAST CANCER (BC) WITH SIMILAR GENETIC ANCESTRY (GA) IN A CLINICOGENOMIC DATABASE (CGDB). 6524 RACIAL, ETHNIC, AND SOCIOECONOMIC DISPARITIES IN TREATMENT OUTCOMES IN PATIENTS (PTS) WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): A U.S. REAL-WORLD STUDY USING A DE-IDENTIFIED ELECTRONIC HEALTH RECORD (EHR)-DERIVED DATABASE. E18514 TUMOR AGNOSTIC ALECENSA ALPHA-T: AN INNOVATIVE DECENTRALIZED (HOME-BASED) PHASE 2 TRIAL OF ALECTINIB IN ALK-POSITIVE (ALK+) SOLID TUMORS IN A HISTOLOGY-AGNOSTIC SETTING. TPS3155 GAVRETO CLINICAL ACTIVITY AND SAFETY OF THE RET INHIBITOR PRALSETINIB IN PATIENTS WITH RET FUSION-POSITIVE SOLID TUMORS: UPDATE FROM THE ARROW TRIAL. 3079 ROZLYTREK, ALECENSA, TECENTRIQ, IPATASERTIB, KADCYLA, INAVOLISIB TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONALE FOR YOU (TAPISTRY): A NOVEL PLATFORM UMBRELLA TRIAL. TPS3154 ROZLYTREK, INAVOLISIB, IPATASERTIB, TECENTRIQ, KADCYLA, PERJETA, HERCEPTIN A STUDY EVALUATING TARGETED THERAPIES IN PARTICIPANTS WHO HAVE ADVANCED SOLID TUMORS WITH GENOMIC ALTERATIONS OR PROTEIN EXPRESSION PATTERNS PREDICTIVE OF RESPONSE (MYTACTIC). TPS1588 ABOUT GAVRETO GAVRETO IS A ONCE-DAILY, ORAL PRECISION THERAPY DESIGNED TO SELECTIVELY TARGET RET ALTERATIONS, INCLUDING FUSIONS AND MUTATIONS, REGARDLESS OF THE TISSUE OF ORIGIN. PRECLINICAL DATA HAVE SHOWN THAT GAVRETO INHIBITS PRIMARY RET FUSIONS AND MUTATIONS THAT CAUSE CANCER IN SUBSETS OF PATIENTS, AS WELL AS SECONDARY RET MUTATIONS PREDICTED TO DRIVE RESISTANCE TO TREATMENT. BLUEPRINT MEDICINES AND GENENTECH ARE CO-DEVELOPING GAVRETO FOR THE TREATMENT OF PATIENTS WITH VARIOUS TYPES OF RET-ALTERED CANCERS. GAVRETO™ U.S. INDICATIONS GAVRETO™ IS A PRESCRIPTION MEDICINE USED TO TREAT CERTAIN CANCERS CAUSED BY ABNORMAL REARRANGED DURING TRANSFECTION (RET) GENE IN: ADULTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) THAT HAS SPREAD ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER WITH ADVANCED MEDULLARY THYROID CANCER (MTC) OR MTC THAT HAS SPREAD WHO REQUIRE A MEDICINE BY MOUTH OR INJECTION (SYSTEMIC THERAPY) ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER WITH ADVANCED THYROID CANCER OR THYROID CANCER THAT HAS SPREAD WHO REQUIRE A MEDICINE BY MOUTH OR INJECTION (SYSTEMIC THERAPY) AND WHO HAVE RECEIVED RADIOACTIVE IODINE AND IT DID NOT WORK OR IS NO LONGER WORKING A PATIENT’S HEALTHCARE PROVIDER WILL PERFORM A TEST TO MAKE SURE THAT GAVRETO IS RIGHT FOR THEM. GAVRETO WAS APPROVED BASED ON THE PERCENTAGE OF PATIENTS WHOSE TUMOR SIZE SHRANK OR DISAPPEARED AFTER TREATMENT AND HOW LONG THAT RESPONSE LASTED. THERE ARE ONGOING STUDIES TO CONFIRM THE BENEFIT OF GAVRETO. IMPORTANT SAFETY INFORMATION GAVRETO MAY CAUSE SERIOUS SIDE EFFECTS, INCLUDING LUNG PROBLEMS: GAVRETO MAY CAUSE SEVERE OR LIFE-THREATENING INFLAMMATION OF THE LUNGS DURING TREATMENT, THAT CAN LEAD TO DEATH. PATIENTS SHOULD TELL THEIR HEALTHCARE PROVIDER RIGHT AWAY IF THEY HAVE ANY NEW OR WORSENING SYMPTOMS, INCLUDING SHORTNESS OF BREATH, COUGH, OR FEVER. HIGH BLOOD PRESSURE (HYPERTENSION): HIGH BLOOD PRESSURE IS COMMON WITH GAVRETO AND MAY SOMETIMES BE SEVERE. PATIENTS SHOULD CHECK THEIR BLOOD PRESSURE REGULARLY DURING TREATMENT WITH GAVRETO. PATIENTS SHOULD TELL THEIR HEALTHCARE PROVIDER IF THEY HAVE INCREASED BLOOD PRESSURE READINGS OR GET ANY SYMPTOMS OF HIGH BLOOD PRESSURE, INCLUDING CONFUSION, DIZZINESS, HEADACHES, CHEST PAIN OR SHORTNESS OF BREATH. LIVER PROBLEMS: LIVER PROBLEMS (INCREASED LIVER FUNCTION BLOOD TEST RESULTS) CAN HAPPEN DURING TREATMENT WITH GAVRETO AND MAY SOMETIMES BE SERIOUS. A HEALTHCARE PROVIDER WILL DO BLOOD TESTS BEFORE AND DURING TREATMENT WITH GAVRETO TO CHECK PATIENTS FOR LIVER PROBLEMS. PATIENTS SHOULD TELL THEIR HEALTHCARE PROVIDER RIGHT AWAY IF THEY GET ANY SIGNS OR SYMPTOMS OF LIVER PROBLEM DURING TREATMENT, INCLUDING YELLOWING OF THEIR SKIN OR THE WHITE PART OF THEIR EYES (JAUNDICE), LOSS OF APPETITE, NAUSEA OR VOMITING, DARK “TEA-COLORED” URINE, PAIN ON THE UPPER RIGHT SIDE OF THEIR STOMACH AREA, SLEEPINESS, BLEEDING OR BRUISING. BLEEDING PROBLEMS: GAVRETO CAN CAUSE BLEEDING WHICH CAN BE SERIOUS AND CAUSE DEATH. PATIENTS SHOULD TELL THEIR HEALTHCARE PROVIDER IF THEY HAVE ANY SIGNS OR SYMPTOMS OF BLEEDING DURING TREATMENT, INCLUDING VOMITING BLOOD OR IF THEIR VOMIT LOOKS LIKE COFFEE-GROUNDS, UNUSUAL VAGINAL BLEEDING, NOSE BLEEDS THAT HAPPEN OFTEN, PINK OR BROWN URINE, DROWSINESS OR DIFFICULTY BEING AWAKENED, RED OR BLACK (LOOKS LIKE TAR) STOOLS, CONFUSION, COUGHING UP BLOOD OR BLOOD CLOTS, HEADACHE, UNUSUAL BLEEDING OR BRUISING OF THEIR SKIN, CHANGE IN SPEECH, OR MENSTRUAL BLEEDING THAT IS HEAVIER THAN NORMAL. TUMOR LYSIS SYNDROME (TLS): TLS IS CAUSED BY A FAST BREAKDOWN OF CANCER CELLS. TLS CAN CAUSE PATIENTS TO HAVE KIDNEY FAILURE AND THE NEED FOR DIALYSIS TREATMENT, AN ABNORMAL HEARTBEAT, AND MAY SOMETIMES LEAD TO HOSPITALIZATION. A HEALTHCARE PROVIDER MAY DO BLOOD TESTS TO CHECK PATIENTS FOR TLS. PATIENTS SHOULD STAY WELL HYDRATED DURING TREATMENT WITH GAVRETO. PATIENTS SHOULD CALL THEIR HEALTHCARE PROVIDER OR GET EMERGENCY MEDICAL HELP RIGHT AWAY IF THEY DEVELOP ANY OF THESE SYMPTOMS DURING TREATMENT WITH GAVRETO: NAUSEA, SHORTNESS OF BREATH, VOMITING, MUSCLE CRAMPS, WEAKNESS, SEIZURES OR SWELLING. RISK OF WOUND HEALING PROBLEMS: WOUNDS MAY NOT HEAL PROPERLY DURING TREATMENT WITH GAVRETO. PATIENTS SHOULD TELL THEIR HEALTHCARE PROVIDER IF THEY PLAN TO HAVE ANY SURGERY BEFORE OR DURING TREATMENT WITH GAVRETO. PATIENTS SHOULD NOT TAKE GAVRETO FOR AT LEAST 5 DAYS BEFORE SURGERY. A HEALTHCARE PROVIDER SHOULD TELL PATIENTS WHEN THEY MAY START TAKING GAVRETO AGAIN AFTER SURGERY. BEFORE TAKING GAVRETO, PATIENTS SHOULD TELL THEIR HEALTHCARE PROVIDER ABOUT ALL OF THEIR MEDICAL CONDITIONS, INCLUDING IF THEY: HAVE LUNG OR BREATHING PROBLEMS OTHER THAN LUNG CANCER HAVE HIGH BLOOD PRESSURE HAVE BLEEDING PROBLEMS PLAN TO HAVE SURGERY ARE PREGNANT OR PLAN TO BECOME PREGNANT. GAVRETO CAN HARM AN UNBORN BABY. FEMALES WHO ARE ABLE TO BECOME PREGNANT: A HEALTHCARE PROVIDER WILL DO A PREGNANCY TEST BEFORE PATIENTS START GAVRETO. SHOULD USE AN EFFECTIVE FORM OF NON-HORMONAL BIRTH CONTROL (CONTRACEPTION) DURING TREATMENT WITH GAVRETO AND FOR 2 WEEKS AFTER THE FINAL DOSE OF GAVRETO. BIRTH CONTROL METHODS THAT CONTAIN HORMONES (SUCH AS BIRTH CONTROL PILLS, INJECTIONS OR TRANSDERMAL SYSTEM PATCHES) MAY NOT WORK AS WELL DURING TREATMENT WITH GAVRETO. PATIENTS SHOULD TALK TO THEIR HEALTHCARE PROVIDER ABOUT BIRTH CONTROL METHODS THAT MAY BE RIGHT FOR THEM DURING THIS TIME. PATIENTS SHOULD TELL THEIR HEALTHCARE PROVIDER RIGHT AWAY IF THEY BECOME PREGNANT OR THINK THEY MIGHT BE PREGNANT DURING TREATMENT WITH GAVRETO. MALES WITH FEMALE PARTNERS WHO ARE ABLE TO BECOME PREGNANT SHOULD USE EFFECTIVE BIRTH CONTROL (CONTRACEPTION) DURING TREATMENT AND FOR 1 WEEK AFTER THEIR FINAL DOSE OF GAVRETO. ARE BREASTFEEDING OR PLAN TO BREASTFEED. IT IS NOT KNOWN IF GAVRETO PASSES INTO BREAST MILK. PATIENTS SHOULD NOT BREASTFEED DURING TREATMENT AND FOR 1 WEEK AFTER THEIR LAST DOSE OF GAVRETO. PATIENTS SHOULD TELL THEIR HEALTHCARE PROVIDER ABOUT ALL THE MEDICINES THEY TAKE, INCLUDING PRESCRIPTION AND OVER-THE-COUNTER MEDICINES, VITAMINS, AND HERBAL SUPPLEMENTS. GAVRETO MAY AFFECT THE WAY OTHER MEDICINES WORK, AND OTHER MEDICINES MAY AFFECT HOW GAVRETO WORKS. THE MOST COMMON SIDE EFFECTS OF GAVRETO INCLUDE: CONSTIPATION, DECREASED LEVELS OF PHOSPHATE IN THE BLOOD, HIGH BLOOD PRESSURE, DECREASED LEVELS OF CALCIUM IN THE BLOOD, TIREDNESS, DECREASED LEVELS OF BODY SALT (SODIUM) IN THE BLOOD, MUSCLE AND JOINT PAIN, DIARRHEA, ABNORMAL LIVER FUNCTION BLOOD TESTS, AND DECREASED WHITE BLOOD CELL, RED BLOOD CELL, AND PLATELET COUNTS. GAVRETO MAY AFFECT FERTILITY IN MALES AND FEMALES, WHICH MAY AFFECT A PATIENT’S ABILITY TO HAVE CHILDREN. PATIENTS SHOULD TALK TO THEIR HEALTHCARE PROVIDER IF THIS IS A CONCERN FOR THEM. THESE ARE NOT ALL OF THE POSSIBLE SIDE EFFECTS OF GAVRETO. PATIENTS SHOULD CALL THEIR DOCTOR FOR MEDICAL ADVICE ABOUT SIDE EFFECTS. PATIENTS ARE ENCOURAGED TO REPORT SIDE EFFECTS TO THE FDA. VISIT FDA MEDWATCH OR CALL 1-800-FDA-1088. PLEASE SEE THE FULL PRESCRIBING INFORMATION AND PATIENT INFORMATION FOR GAVRETO. BLUEPRINT MEDICINES, GAVRETO, YOURBLUEPRINT AND ASSOCIATED LOGOS ARE TRADEMARKS OF BLUEPRINT MEDICINES CORPORATION. ABOUT POLIVY™ (POLATUZUMAB VEDOTIN-PIIQ) POLIVY IS A FIRST-IN-CLASS ANTI-CD79B ANTIBODY-DRUG CONJUGATE (ADC). THE CD79B PROTEIN IS EXPRESSED SPECIFICALLY IN THE MAJORITY OF B-CELLS, AN IMMUNE CELL IMPACTED IN SOME TYPES OF NON-HODGKIN’S LYMPHOMA (NHL), MAKING IT A PROMISING TARGET FOR THE DEVELOPMENT OF NEW THERAPIES. POLIVY BINDS TO CD79B AND DESTROYS THESE B-CELLS THROUGH THE DELIVERY OF AN ANTI-CANCER AGENT, WHICH IS THOUGHT TO MINIMIZE THE EFFECTS ON NORMAL CELLS. POLIVY IS BEING DEVELOPED BY ROCHE USING SEATTLE GENETICS ADC TECHNOLOGY AND IS CURRENTLY BEING INVESTIGATED FOR THE TREATMENT OF SEVERAL TYPES OF NHL. POLIVY U.S. INDICATION POLIVY IS A PRESCRIPTION MEDICINE USED WITH OTHER MEDICINES, BENDAMUSTINE AND A RITUXIMAB PRODUCT, TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA IN ADULTS WHO HAVE PROGRESSED AFTER AT LEAST TWO PRIOR THERAPIES. THE ACCELERATED APPROVAL OF POLIVY IS BASED ON A TYPE OF RESPONSE RATE. THERE ARE ONGOING STUDIES TO CONFIRM THE CLINICAL BENEFIT OF POLIVY. IMPORTANT SAFETY INFORMATION POSSIBLE SERIOUS SIDE EFFECTS EVERYONE REACTS DIFFERENTLY TO POLIVY THERAPY, SO IT’S IMPORTANT TO KNOW WHAT THE SIDE EFFECTS ARE. SOME PEOPLE WHO HAVE BEEN TREATED WITH POLIVY HAVE EXPERIENCED SERIOUS TO FATAL SIDE EFFECTS. A PATIENT’S DOCTOR MAY STOP OR ADJUST A PATIENT’S TREATMENT IF ANY SERIOUS SIDE EFFECTS OCCUR. PATIENTS MUST CONTACT THEIR HEALTHCARE TEAM IF THERE ARE ANY SIGNS OF THESE SIDE EFFECTS. NERVE PROBLEMS IN ARMS AND LEGS: THIS MAY HAPPEN AS EARLY AS AFTER THE FIRST DOSE AND MAY WORSEN WITH EVERY DOSE. IF A PATIENT ALREADY HAS NERVE PAIN, POLIVY MAY MAKE IT WORSE. THE PATIENT’S DOCTOR WILL MONITOR FOR SIGNS AND SYMPTOMS, SUCH AS CHANGES IN SENSE OF TOUCH, NUMBNESS OR TINGLING IN HANDS OR FEET, NERVE PAIN, BURNING SENSATION, ANY MUSCLE WEAKNESS, OR CHANGES TO WALKING PATTERNS INFUSION-RELATED REACTIONS: A PATIENT MAY EXPERIENCE FEVER, CHILLS, RASH, BREATHING PROBLEMS, LOW BLOOD PRESSURE, OR HIVES WITHIN 24 HOURS OF THE INFUSION INFECTIONS: PATIENTS SHOULD CONTACT THEIR HEALTHCARE TEAM, IF THEY EXPERIENCE A FEVER OF 100.4°F OR HIGHER, CHILLS, COUGH, OR PAIN DURING URINATION. ALSO, A PATIENT’S DOCTOR MAY GIVE MEDICATION BEFORE GIVING POLIVY, WHICH MAY PREVENT SOME INFECTIONS, AND MONITOR BLOOD COUNTS THROUGHOUT TREATMENT WITH POLIVY. TREATMENT WITH POLIVY CAN CAUSE SEVERE LOW BLOOD CELL COUNTS RARE AND SERIOUS BRAIN INFECTIONS: A PATIENT’S DOCTOR WILL MONITOR THE PATIENT CLOSELY FOR SIGNS AND SYMPTOMS OF THESE TYPES OF INFECTIONS. PATIENTS SHOULD CONTACT THEIR DOCTOR IF THEY EXPERIENCE CONFUSION, DIZZINESS OR LOSS OF BALANCE, TROUBLE TALKING OR WALKING, OR VISION CHANGES TUMOR LYSIS SYNDROME: CAUSED BY THE FAST BREAKDOWN OF CANCER CELLS. SIGNS INCLUDE NAUSEA, VOMITING, DIARRHEA, AND LACK OF ENERGY POTENTIAL HARM TO LIVER: SOME SIGNS INCLUDE TIREDNESS, WEIGHT LOSS, PAIN IN THE ABDOMEN, DARK URINE, AND YELLOWING OF THE SKIN OR THE WHITE PART OF THE EYES. PATIENTS MAY BE AT HIGHER RISK IF THEY ALREADY HAVE LIVER PROBLEMS OR ARE TAKING OTHER MEDICATION SIDE EFFECTS SEEN MOST OFTEN THE MOST COMMON SIDE EFFECTS DURING TREATMENT WERE LOW BLOOD CELL COUNTS (PLATELETS, RED BLOOD CELLS, WHITE BLOOD CELLS) NERVE PROBLEMS IN ARMS AND LEGS TIREDNESS OR LACK OF ENERGY DIARRHEA NAUSEA FEVER DECREASED APPETITE INFECTIONS POLIVY MAY NOT BE FOR EVERYONE. A PATIENT SHOULD TALK TO THEIR DOCTOR IF THEY ARE PREGNANT OR MAY BE PREGNANT: DATA HAVE SHOWN THAT POLIVY MAY HARM AN UNBORN BABY PLANNING TO BECOME PREGNANT: WOMEN SHOULD AVOID GETTING PREGNANT WHILE TAKING POLIVY. WOMEN SHOULD USE EFFECTIVE CONTRACEPTION DURING TREATMENT AND FOR AT LEAST 3 MONTHS AFTER THEIR LAST POLIVY TREATMENT. MEN TAKING POLIVY SHOULD USE EFFECTIVE CONTRACEPTION DURING TREATMENT AND FOR AT LEAST 5 MONTHS AFTER THEIR LAST POLIVY TREATMENT BREASTFEEDING: WOMEN SHOULD NOT BREASTFEED WHILE TAKING POLIVY AND FOR AT LEAST 2 MONTHS AFTER THE LAST DOSE THESE MAY NOT BE ALL THE SIDE EFFECTS. PATIENTS SHOULD TALK TO THEIR HEALTHCARE PROVIDER FOR MORE INFORMATION ABOUT THE BENEFITS AND RISKS OF POLIVY TREATMENT. REPORT SIDE EFFECTS TO THE FDA AT (800) FDA-1088 OR HTTP://WWW.FDA.GOV/MEDWATCH. REPORT SIDE EFFECTS TO GENENTECH AT (888) 835-2555. PLEASE VISIT HTTP://WWW.POLIVY.COM FOR THE FULL PRESCRIBING INFORMATION FOR ADDITIONAL IMPORTANT SAFETY INFORMATION. ABOUT TECENTRIQ (ATEZOLIZUMAB) TECENTRIQ IS A MONOCLONAL ANTIBODY DESIGNED TO BIND WITH A PROTEIN CALLED PD-L1. TECENTRIQ IS DESIGNED TO BIND TO PD-L1 EXPRESSED ON TUMOR CELLS AND TUMOR-INFILTRATING IMMUNE CELLS, BLOCKING ITS INTERACTIONS WITH BOTH PD-1 AND B7.1 RECEPTORS. BY INHIBITING PD-L1, TECENTRIQ MAY ENABLE THE RE-ACTIVATION OF T CELLS. TECENTRIQ MAY ALSO AFFECT NORMAL CELLS. TECENTRIQ U.S. INDICATIONS TECENTRIQ IS A PRESCRIPTION MEDICINE USED TO TREAT ADULTS WITH: A TYPE OF LUNG CANCER CALLED NON-SMALL CELL LUNG CANCER (NSCLC). TECENTRIQ MAY BE USED ALONE AS THE FIRST TREATMENT IN PATIENTS WITH LUNG CANCER IF: THEIR CANCER HAS SPREAD OR GROWN, AND THEIR CANCER TESTS POSITIVE FOR “HIGH PD-L1”, AND THEIR TUMOR DOES NOT HAVE AN ABNORMAL “EGFR” OR “ALK” GENE. TECENTRIQ MAY BE USED WITH THE MEDICINES BEVACIZUMAB, PACLITAXEL, AND CARBOPLATIN AS THE FIRST TREATMENT IN PATIENTS WITH LUNG CANCER IF: THEIR CANCER HAS SPREAD OR GROWN AND IS A TYPE OF LUNG CANCER CALLED “NON-SQUAMOUS NSCLC”, AND THEIR TUMOR DOES NOT HAVE AN ABNORMAL “EGFR” OR “ALK” GENE. TECENTRIQ MAY BE USED WITH THE MEDICINES PACLITAXEL PROTEIN-BOUND AND CARBOPLATIN AS THE FIRST TREATMENT IN PATIENTS WITH LUNG CANCER IF: THEIR CANCER HAS SPREAD OR GROWN, AND IS A TYPE OF LUNG CANCER CALLED “NON-SQUAMOUS NSCLC”, AND THEIR TUMOR DOES NOT HAVE AN ABNORMAL “EGFR” OR “ALK” GENE. TECENTRIQ MAY BE USED ALONE IN PATIENTS WITH LUNG CANCER IF: THEIR CANCER HAS SPREAD OR GROWN, AND THEY HAVE TRIED CHEMOTHERAPY THAT CONTAINS PLATINUM, AND IT DID NOT WORK OR IS NO LONGER WORKING. IF A PATIENT’S TUMOR HAS AN ABNORMAL “EGFR” OR “ALK” GENE, THEY SHOULD HAVE ALSO TRIED AN FDA-APPROVED THERAPY FOR TUMORS WITH THESE ABNORMAL GENES, AND IT DID NOT WORK OR IS NO LONGER WORKING. A TYPE OF BREAST CANCER CALLED TRIPLE-NEGATIVE BREAST CANCER (TNBC). TECENTRIQ MAY BE USED WITH THE MEDICINE PACLITAXEL PROTEIN-BOUND IN PATIENTS WITH TNBC WHEN THEIR BREAST CANCER: HAS SPREAD OR CANNOT BE REMOVED BY SURGERY. AND THEIR CANCER TESTS POSITIVE FOR “PD-L1”. THE APPROVAL OF TECENTRIQ IN THESE PATIENTS IS BASED ON A STUDY THAT MEASURED THE AMOUNT OF TIME UNTIL PATIENTS’ DISEASE WORSENED. CONTINUED APPROVAL FOR THIS USE MAY DEPEND ON THE RESULTS OF AN ONGOING STUDY TO CONFIRM BENEFIT. TECENTRIQ IS NOT FOR USE WITH THE MEDICINE PACLITAXEL (A DIFFERENT MEDICINE THAN PACLITAXEL PROTEIN-BOUND) IN PATIENTS WITH TNBC WHEN THEIR BREAST CANCER HAS SPREAD OR CANNOT BE REMOVED BY SURGERY. A TYPE OF LIVER CANCER CALLED HEPATOCELLULAR CARCINOMA (HCC). TECENTRIQ MAY BE USED WITH THE MEDICINE BEVACIZUMAB IN PATIENTS WITH HCC IF: THEIR CANCER HAS SPREAD OR CANNOT BE REMOVED BY SURGERY, AND THEY HAVE NOT RECEIVED OTHER MEDICINES BY MOUTH OR INJECTION THROUGH THEIR VEIN (IV) TO TREAT THEIR CANCER. IT IS NOT KNOWN IF TECENTRIQ IS SAFE AND EFFECTIVE IN CHILDREN. IMPORTANT SAFETY INFORMATION THE MOST IMPORTANT INFORMATION ABOUT TECENTRIQ IS: TECENTRIQ CAN CAUSE THE IMMUNE SYSTEM TO ATTACK NORMAL ORGANS AND TISSUES AND CAN AFFECT THE WAY THEY WORK. THESE PROBLEMS CAN SOMETIMES BECOME SERIOUS OR LIFE-THREATENING AND CAN LEAD TO DEATH. PATIENTS CAN HAVE MORE THAN ONE OF THESE PROBLEMS AT THE SAME TIME. THESE PROBLEMS MAY HAPPEN ANYTIME DURING TREATMENT OR EVEN AFTER TREATMENT HAS ENDED. PATIENTS SHOULD CALL OR SEE THEIR HEALTHCARE PROVIDER RIGHT AWAY IF THEY DEVELOP ANY NEW OR WORSE SIGNS OF SYMPTOMS, INCLUDING: LUNG PROBLEMS COUGH SHORTNESS OF BREATH CHEST PAIN INTESTINAL PROBLEMS DIARRHEA (LOOSE STOOLS) OR MORE BOWEL MOVEMENTS THAN USUAL STOOLS THAT ARE BLACK, TARRY, STICKY, OR HAVE BLOOD OR MUCUS SEVERE STOMACH AREA (ABDOMEN) PAIN OR TENDERNESS LIVER PROBLEMS YELLOWING OF THE SKIN OR THE WHITES OF THE EYES SEVERE NAUSEA OR VOMITING PAIN ON THE RIGHT SIDE OF THE STOMACH AREA (ABDOMEN) DARK URINE (TEA-COLORED) BLEEDING OR BRUISING MORE EASILY THAN NORMAL AND FEELING LESS HUNGRY THAN USUAL HORMONE GLAND PROBLEMS HEADACHES THAT WILL NOT GO AWAY OR UNUSUAL HEADACHES EYE SENSITIVITY TO LIGHT EYE PROBLEMS RAPID HEARTBEAT INCREASED SWEATING EXTREME TIREDNESS WEIGHT GAIN OR WEIGHT LOSS CHANGES IN MOOD OR BEHAVIOR, SUCH AS DECREASED SEX DRIVE, IRRITABILITY, OR FORGETFULNESS FEELING MORE HUNGRY OR THIRSTY THAN USUAL URINATING MORE OFTEN THAN USUAL HAIR LOSS FEELING COLD CONSTIPATION THE VOICE GETS DEEPER DIZZINESS OR FAINTING KIDNEY PROBLEMS DECREASE IN THE AMOUNT OF URINE BLOOD IN THE URINE SWELLING OF ANKLES LOSS OF APPETITE SKIN PROBLEMS RASH ITCHING SKIN BLISTERING OR PEELING PAINFUL SORES OR ULCERS IN MOUTH OR NOSE, THROAT, OR GENITAL AREA FEVER OR FLU-LIKE SYMPTOMS SWOLLEN LYMPH NODES PROBLEMS CAN ALSO HAPPEN IN OTHER ORGANS. THESE ARE NOT ALL OF THE SIGNS AND SYMPTOMS OF IMMUNE SYSTEM PROBLEMS THAT CAN HAPPEN WITH TECENTRIQ. PATIENTS SHOULD CALL OR SEE THEIR HEALTHCARE PROVIDER RIGHT AWAY FOR ANY NEW OR WORSE SIGNS OR SYMPTOMS, INCLUDING: CHEST PAIN, IRREGULAR HEARTBEAT, SHORTNESS OF BREATH, OR SWELLING OF ANKLES CONFUSION, SLEEPINESS, MEMORY PROBLEMS, CHANGES IN MOOD OR BEHAVIOR, STIFF NECK, BALANCE PROBLEMS, TINGLING OR NUMBNESS OF THE ARMS OR LEGS DOUBLE VISION, BLURRY VISION, SENSITIVITY TO LIGHT, EYE PAIN, CHANGES IN EYESIGHT PERSISTENT OR SEVERE MUSCLE PAIN OR WEAKNESS, MUSCLE CRAMPS LOW RED BLOOD CELLS, BRUISING INFUSION REACTIONS THAT CAN SOMETIMES BE SEVERE OR LIFE-THREATENING. SIGNS AND SYMPTOMS OF INFUSION REACTIONS MAY INCLUDE: CHILLS OR SHAKING ITCHING OR RASH FLUSHING SHORTNESS OF BREATH OR WHEEZING DIZZINESS FEELING LIKE PASSING OUT FEVER BACK OR NECK PAIN COMPLICATIONS, INCLUDING GRAFT-VERSUS-HOST DISEASE (GVHD), IN PEOPLE WHO HAVE RECEIVED A BONE MARROW (STEM CELL) TRANSPLANT THAT USES DONOR STEM CELLS (ALLOGENEIC). THESE COMPLICATIONS CAN BE SERIOUS AND CAN LEAD TO DEATH. THESE COMPLICATIONS MAY HAPPEN IF A PATIENT UNDERWENT TRANSPLANTATION EITHER BEFORE OR AFTER BEING TREATED WITH TECENTRIQ. A PATIENT’S HEALTHCARE PROVIDER WILL MONITOR THEM FOR THESE COMPLICATIONS. GETTING MEDICAL TREATMENT RIGHT AWAY MAY HELP KEEP THESE PROBLEMS FROM BECOMING MORE SERIOUS. A HEALTHCARE PROVIDER WILL CHECK PATIENTS FOR THESE PROBLEMS DURING THEIR TREATMENT WITH TECENTRIQ. A HEALTHCARE PROVIDER MAY TREAT PATIENTS WITH CORTICOSTEROID OR HORMONE REPLACEMENT MEDICINES. A HEALTHCARE PROVIDER MAY ALSO NEED TO DELAY OR COMPLETELY STOP TREATMENT WITH TECENTRIQ IF PATIENTS HAVE SEVERE SIDE EFFECTS. BEFORE RECEIVING TECENTRIQ, PATIENTS SHOULD TELL THEIR HEALTHCARE PROVIDER ABOUT ALL OF THEIR MEDICAL CONDITIONS, INCLUDING IF THEY: HAVE IMMUNE SYSTEM PROBLEMS SUCH AS CROHN’S DISEASE, ULCERATIVE COLITIS, OR LUPUS HAVE HAD AN ORGAN TRANSPLANT HAVE RECEIVED OR PLAN TO RECEIVE A STEM CELL TRANSPLANT THAT USES DONOR STEM CELLS (ALLOGENEIC) HAVE RECEIVED RADIATION TREATMENT TO THEIR CHEST AREA HAVE A CONDITION THAT AFFECTS THE NERVOUS SYSTEM (SUCH AS MYASTHENIA GRAVIS OR GUILLAIN-BARRE SYNDROME ARE PREGNANT OR PLAN TO BECOME PREGNANT. TECENTRIQ CAN HARM AN UNBORN BABY. PATIENTS SHOULD TELL THEIR HEALTHCARE PROVIDER RIGHT AWAY IF THEY BECOME PREGNANT OR THINK THEY MAY BE PREGNANT DURING TREATMENT WITH TECENTRIQ. FEMALES WHO ARE ABLE TO BECOME PREGNANT: SHOULD HAVE A HEALTHCARE PROVIDER DO A PREGNANCY TEST BEFORE THEY START TREATMENT WITH TECENTRIQ. SHOULD USE AN EFFECTIVE METHOD OF BIRTH CONTROL DURING THEIR TREATMENT AND FOR AT LEAST 5 MONTHS AFTER THE LAST DOSE OF TECENTRIQ. SHOULD HAVE A HEALTHCARE PROVIDER DO A PREGNANCY TEST BEFORE THEY START TREATMENT WITH TECENTRIQ. SHOULD USE AN EFFECTIVE METHOD OF BIRTH CONTROL DURING THEIR TREATMENT AND FOR AT LEAST 5 MONTHS AFTER THE LAST DOSE OF TECENTRIQ. ARE BREASTFEEDING OR PLAN TO BREASTFEED. IT IS NOT KNOWN IF TECENTRIQ PASSES INTO BREAST MILK. PATIENTS SHOULD NOT BREASTFEED DURING TREATMENT AND FOR AT LEAST 5 MONTHS AFTER THE LAST DOSE OF TECENTRIQ. PATIENTS SHOULD TELL THEIR HEALTHCARE PROVIDER ABOUT ALL THE MEDICINES THEY TAKE, INCLUDING PRESCRIPTION AND OVER-THE-COUNTER MEDICINES, VITAMINS, AND HERBAL SUPPLEMENTS. THE MOST COMMON SIDE EFFECTS OF TECENTRIQ WHEN USED ALONE INCLUDE: FEELING TIRED OR WEAK NAUSEA COUGH SHORTNESS OF BREATH DECREASED APPETITE THE MOST COMMON SIDE EFFECTS OF TECENTRIQ WHEN USED IN LUNG CANCER WITH OTHER ANTI-CANCER MEDICINES INCLUDE: FEELING TIRED OR WEAK NAUSEA HAIR LOSS CONSTIPATION DIARRHEA DECREASED APPETITE THE MOST COMMON SIDE EFFECTS OF TECENTRIQ WHEN USED IN TNBC WITH PACLITAXEL PROTEIN-BOUND INCLUDE: DECREASE IN HEMOGLOBIN (ANEMIA) DECREASED WHITE BLOOD CELLS HAIR LOSS TINGLING OR NUMBNESS IN HANDS AND FEET FEELING TIRED NAUSEA DIARRHEA CONSTIPATION COUGH HEADACHE VOMITING DECREASED APPETITE THE MOST COMMON SIDE EFFECTS OF TECENTRIQ WHEN USED IN HEPATOCELLULAR CARCINOMA (HCC) WITH BEVACIZUMAB INCLUDE: HIGH BLOOD PRESSURE FEELING TIRED OR WEAK TOO MUCH PROTEIN IN THE URINE TECENTRIQ MAY CAUSE FERTILITY PROBLEMS IN FEMALES, WHICH MAY AFFECT THEIR ABILITY TO HAVE CHILDREN. PATIENTS SHOULD TALK TO THEIR HEALTHCARE PROVIDER IF THEY HAVE CONCERNS ABOUT FERTILITY. THESE ARE NOT ALL THE POSSIBLE SIDE EFFECTS OF TECENTRIQ. PATIENTS SHOULD ASK THEIR HEALTHCARE PROVIDER OR PHARMACIST FOR MORE INFORMATION ABOUT THE BENEFITS AND SIDE EFFECTS OF TECENTRIQ. REPORT SIDE EFFECTS TO THE FDA AT (800) FDA-1088 OR HTTP://WWW.FDA.GOV/MEDWATCH. REPORT SIDE EFFECTS TO GENENTECH AT (888) 835-2555. PLEASE VISIT HTTP://WWW.TECENTRIQ.COM FOR THE FULL TECENTRIQ PRESCRIBING INFORMATION AND MEDICATION GUIDE FOR ADDITIONAL IMPORTANT SAFETY INFORMATION. BLUEPRINT MEDICINES AND ROCHE ARE CO-DEVELOPING GAVRETO (PRALSETINIB) GLOBALLY, EXCLUDING GREATER CHINA.* BLUEPRINT MEDICINES AND GENENTECH, A WHOLLY-OWNED MEMBER OF THE ROCHE GROUP, ARE COMMERCIALIZING GAVRETO IN THE US AND ROCHE HAS EXCLUSIVE COMMERCIALIZATION RIGHTS FOR GAVRETO OUTSIDE OF THE US, EXCLUDING GREATER CHINA.* *GREATER CHINA ENCOMPASSES MAINLAND CHINA, HONG KONG, MACAU AND TAIWAN. CSTONE PHARMACEUTICALS RETAINS ALL RIGHTS TO THE DEVELOPMENT AND COMMERCIALIZATION OF GAVRETO IN GREATER CHINA UNDER ITS EXISTING COLLABORATION WITH BLUEPRINT MEDICINES. ALL TRADEMARKS USED OR MENTIONED IN THIS RELEASE ARE PROTECTED BY LAW. BLUEPRINT MEDICINES, GAVRETO AND ASSOCIATED LOGOS ARE TRADEMARKS OF BLUEPRINT MEDICINES CORPORATION. ABOUT GENENTECH FOUNDED MORE THAN 40 YEARS AGO, GENENTECH IS A LEADING BIOTECHNOLOGY COMPANY THAT DISCOVERS, DEVELOPS, MANUFACTURES AND COMMERCIALIZES MEDICINES TO TREAT PATIENTS WITH SERIOUS AND LIFE-THREATENING MEDICAL CONDITIONS. THE COMPANY, A MEMBER OF THE ROCHE GROUP, HAS HEADQUARTERS IN SOUTH SAN FRANCISCO, CALIFORNIA. FOR ADDITIONAL INFORMATION ABOUT THE COMPANY, PLEASE VISIT HTTP://WWW.GENE.COM.
- MathCraft Security Technologies, Inc. Promotes Industrial Security Compliance with Access Commander® 4.0
Jul 8, 2020 · businesswire.com
ASHBURN, Va.--(BUSINESS WIRE)--MathCraft Security Technologies, Inc. has announced the release of industrial security compliance solution Access Commander® 4.0. Geared towards Facility Security Officers (FSOs) and other government contracting professionals, Access Commander 4.0 is built for comprehensive compliance with national security regulations including the National Industrial Security Program Operating Manual (NISPOM), Defense Federal Acquisition Regulation Supplement (DFARS) and the DoD’s upcoming Cybersecurity Model Maturity Certification (CMMC) program. “We listened to our clients, they wanted one solution for comprehensive governance and oversight. We have developed a single-platform solution for the government contracting industry," according to Imo Etuk, President/CEO of MathCraft. Available on-premise or cloud, the software now includes a redesigned user interface, dashboards, enhanced Insider Threat analysis, modules to address Security Executive Agent Directive (SEAD) 3 through SEAD 7 reporting requirements, Counterintelligence, Foreign Travel, Suspicious Contacts and more. Access Commander completes MathCraft’s Enterprise Security Suite, that also includes Portal Commander and ViSi Commander. These three tools provide comprehensive industrial security management, visitor management, workflow and self-service functionalities to cleared contractors. When asked about competing solutions, Etuk said, “No other vendor provides this much functionality; our products are designed to be the last word on compliance.” The Next Generation of Threats Last year, over 4 billion sensitive or classified records were exposed through data breaches. According to a 2018 MITRE report, a majority of government contractors were not in compliance with federal standards like DFARS 7012 or NIST 800-171. As a result of these increased security threats, regulators have proposed initiatives like CMMC to impose stricter security requirements on private businesses operating in the federal space. When asked to comment, Etuk said, “The Defense Counterintelligence and Security Agency (DCSA) is stressing counterintelligence, which is the right move. Risk has become a factor of giving the wrong people access to your organization; insider threats, foreign and suspicious contacts - these are all things FSOs track and Access Commander enables them to do just that!” Government contractors will be faced with greater reporting requirements in the future, including the maintenance of strict records for any security incidents or breaches of protocol. For those seeking automated solutions, Etuk says, “It’s our responsibility to stay one step ahead of compliance, so that our clients are prepared to manage and mitigate existing and future threats.” About MathCraft Security Technologies, Inc. MathCraft Security Technologies is the leading provider of innovative software for industrial security professionals. Our solutions support all federal security requirements from the Department of Defense (DoD) regarding Controlled Unclassified Information (CUI), Defense Federal Acquisition Regulation Supplement (DFARS) and more. For further information on MathCraft’s Access Commander® 4.0 or Enterprise Security Suite, call 703-729-9022, email info@mathcraft.com or visit https://www.mathcraft.com/
- MATHCRAFT SECURITY TECHNOLOGIES, INC. PROMOTES INDUSTRIAL SECURITY COMPLIANCE WITH ACCESS COMMANDER® 4.0
Jul 8, 2020
ASHBURN, VA.--(BUSINESS WIRE)--MATHCRAFT SECURITY TECHNOLOGIES, INC. HAS ANNOUNCED THE RELEASE OF INDUSTRIAL SECURITY COMPLIANCE SOLUTION ACCESS COMMANDER® 4.0. GEARED TOWARDS FACILITY SECURITY OFFICERS (FSOS) AND OTHER GOVERNMENT CONTRACTING PROFESSIONALS, ACCESS COMMANDER 4.0 IS BUILT FOR COMPREHENSIVE COMPLIANCE WITH NATIONAL SECURITY REGULATIONS INCLUDING THE NATIONAL INDUSTRIAL SECURITY PROGRAM OPERATING MANUAL (NISPOM), DEFENSE FEDERAL ACQUISITION REGULATION SUPPLEMENT (DFARS) AND THE DOD’S UPCOMING CYBERSECURITY MODEL MATURITY CERTIFICATION (CMMC) PROGRAM. “WE LISTENED TO OUR CLIENTS, THEY WANTED ONE SOLUTION FOR COMPREHENSIVE GOVERNANCE AND OVERSIGHT. WE HAVE DEVELOPED A SINGLE-PLATFORM SOLUTION FOR THE GOVERNMENT CONTRACTING INDUSTRY," ACCORDING TO IMO ETUK, PRESIDENT/CEO OF MATHCRAFT. AVAILABLE ON-PREMISE OR CLOUD, THE SOFTWARE NOW INCLUDES A REDESIGNED USER INTERFACE, DASHBOARDS, ENHANCED INSIDER THREAT ANALYSIS, MODULES TO ADDRESS SECURITY EXECUTIVE AGENT DIRECTIVE (SEAD) 3 THROUGH SEAD 7 REPORTING REQUIREMENTS, COUNTERINTELLIGENCE, FOREIGN TRAVEL, SUSPICIOUS CONTACTS AND MORE. ACCESS COMMANDER COMPLETES MATHCRAFT’S ENTERPRISE SECURITY SUITE, THAT ALSO INCLUDES PORTAL COMMANDER AND VISI COMMANDER. THESE THREE TOOLS PROVIDE COMPREHENSIVE INDUSTRIAL SECURITY MANAGEMENT, VISITOR MANAGEMENT, WORKFLOW AND SELF-SERVICE FUNCTIONALITIES TO CLEARED CONTRACTORS. WHEN ASKED ABOUT COMPETING SOLUTIONS, ETUK SAID, “NO OTHER VENDOR PROVIDES THIS MUCH FUNCTIONALITY; OUR PRODUCTS ARE DESIGNED TO BE THE LAST WORD ON COMPLIANCE.” THE NEXT GENERATION OF THREATS LAST YEAR, OVER 4 BILLION SENSITIVE OR CLASSIFIED RECORDS WERE EXPOSED THROUGH DATA BREACHES. ACCORDING TO A 2018 MITRE REPORT, A MAJORITY OF GOVERNMENT CONTRACTORS WERE NOT IN COMPLIANCE WITH FEDERAL STANDARDS LIKE DFARS 7012 OR NIST 800-171. AS A RESULT OF THESE INCREASED SECURITY THREATS, REGULATORS HAVE PROPOSED INITIATIVES LIKE CMMC TO IMPOSE STRICTER SECURITY REQUIREMENTS ON PRIVATE BUSINESSES OPERATING IN THE FEDERAL SPACE. WHEN ASKED TO COMMENT, ETUK SAID, “THE DEFENSE COUNTERINTELLIGENCE AND SECURITY AGENCY (DCSA) IS STRESSING COUNTERINTELLIGENCE, WHICH IS THE RIGHT MOVE. RISK HAS BECOME A FACTOR OF GIVING THE WRONG PEOPLE ACCESS TO YOUR ORGANIZATION; INSIDER THREATS, FOREIGN AND SUSPICIOUS CONTACTS - THESE ARE ALL THINGS FSOS TRACK AND ACCESS COMMANDER ENABLES THEM TO DO JUST THAT!” GOVERNMENT CONTRACTORS WILL BE FACED WITH GREATER REPORTING REQUIREMENTS IN THE FUTURE, INCLUDING THE MAINTENANCE OF STRICT RECORDS FOR ANY SECURITY INCIDENTS OR BREACHES OF PROTOCOL. FOR THOSE SEEKING AUTOMATED SOLUTIONS, ETUK SAYS, “IT’S OUR RESPONSIBILITY TO STAY ONE STEP AHEAD OF COMPLIANCE, SO THAT OUR CLIENTS ARE PREPARED TO MANAGE AND MITIGATE EXISTING AND FUTURE THREATS.” ABOUT MATHCRAFT SECURITY TECHNOLOGIES, INC. MATHCRAFT SECURITY TECHNOLOGIES IS THE LEADING PROVIDER OF INNOVATIVE SOFTWARE FOR INDUSTRIAL SECURITY PROFESSIONALS. OUR SOLUTIONS SUPPORT ALL FEDERAL SECURITY REQUIREMENTS FROM THE DEPARTMENT OF DEFENSE (DOD) REGARDING CONTROLLED UNCLASSIFIED INFORMATION (CUI), DEFENSE FEDERAL ACQUISITION REGULATION SUPPLEMENT (DFARS) AND MORE. FOR FURTHER INFORMATION ON MATHCRAFT’S ACCESS COMMANDER® 4.0 OR ENTERPRISE SECURITY SUITE, CALL 703-729-9022, EMAIL INFO@MATHCRAFT.COM OR VISIT HTTPS://WWW.MATHCRAFT.COM/
- Form 8.3 - SIBANYE GOLD LIMITED
May 22, 2019 · businesswire.com
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. Use a separate form for each offeror/offeree For an opening position disclosure, state the latest practicable date prior to the disclosure If it is a cash offer or possible cash offer, state “N/A” LONMIN PLC 2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security. (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) TOTAL: All interests and all short positions should be disclosed. Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions). (b) Rights to subscribe for new securities (including directors’ and other employee options) 3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in. The currency of all prices and other monetary amounts should be stated. (a) Purchases and sales (b) Cash-settled derivative transactions e.g. CFD e.g. opening/closing a long/short position, increasing/reducing a long/short position (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying e.g. American, European etc. (ii) Exercise e.g. call option (d) Other dealings (including subscribing for new securities) e.g. subscription, conversion 4. OTHER INFORMATION (a) Indemnity and other dealing arrangements Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none” (b) Agreements, arrangements or understandings relating to options or derivatives (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none” (c) Attachments Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129. *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel’s Market Surveillance Unit. The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.
- FORM 8.3 - SIBANYE GOLD LIMITED
May 22, 2019
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE RULE 8.3 OF THE TAKEOVER CODE (THE “CODE”) 1. KEY INFORMATION THE NAMING OF NOMINEE OR VEHICLE COMPANIES IS INSUFFICIENT. FOR A TRUST, THE TRUSTEE(S), SETTLOR AND BENEFICIARIES MUST BE NAMED. USE A SEPARATE FORM FOR EACH OFFEROR/OFFEREE FOR AN OPENING POSITION DISCLOSURE, STATE THE LATEST PRACTICABLE DATE PRIOR TO THE DISCLOSURE IF IT IS A CASH OFFER OR POSSIBLE CASH OFFER, STATE “N/A” LONMIN PLC 2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE IF THERE ARE POSITIONS OR RIGHTS TO SUBSCRIBE TO DISCLOSE IN MORE THAN ONE CLASS OF RELEVANT SECURITIES OF THE OFFEROR OR OFFEREE NAMED IN 1(C), COPY TABLE 2(A) OR (B) (AS APPROPRIATE) FOR EACH ADDITIONAL CLASS OF RELEVANT SECURITY. (A) INTERESTS AND SHORT POSITIONS IN THE RELEVANT SECURITIES OF THE OFFEROR OR OFFEREE TO WHICH THE DISCLOSURE RELATES FOLLOWING THE DEALING (IF ANY) TOTAL: ALL INTERESTS AND ALL SHORT POSITIONS SHOULD BE DISCLOSED. DETAILS OF ANY OPEN STOCK-SETTLED DERIVATIVE POSITIONS (INCLUDING TRADED OPTIONS), OR AGREEMENTS TO PURCHASE OR SELL RELEVANT SECURITIES, SHOULD BE GIVEN ON A SUPPLEMENTAL FORM 8 (OPEN POSITIONS). (B) RIGHTS TO SUBSCRIBE FOR NEW SECURITIES (INCLUDING DIRECTORS’ AND OTHER EMPLOYEE OPTIONS) 3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE WHERE THERE HAVE BEEN DEALINGS IN MORE THAN ONE CLASS OF RELEVANT SECURITIES OF THE OFFEROR OR OFFEREE NAMED IN 1(C), COPY TABLE 3(A), (B), (C) OR (D) (AS APPROPRIATE) FOR EACH ADDITIONAL CLASS OF RELEVANT SECURITY DEALT IN. THE CURRENCY OF ALL PRICES AND OTHER MONETARY AMOUNTS SHOULD BE STATED. (A) PURCHASES AND SALES (B) CASH-SETTLED DERIVATIVE TRANSACTIONS E.G. CFD E.G. OPENING/CLOSING A LONG/SHORT POSITION, INCREASING/REDUCING A LONG/SHORT POSITION (C) STOCK-SETTLED DERIVATIVE TRANSACTIONS (INCLUDING OPTIONS) (I) WRITING, SELLING, PURCHASING OR VARYING E.G. AMERICAN, EUROPEAN ETC. (II) EXERCISE E.G. CALL OPTION (D) OTHER DEALINGS (INCLUDING SUBSCRIBING FOR NEW SECURITIES) E.G. SUBSCRIPTION, CONVERSION 4. OTHER INFORMATION (A) INDEMNITY AND OTHER DEALING ARRANGEMENTS IRREVOCABLE COMMITMENTS AND LETTERS OF INTENT SHOULD NOT BE INCLUDED. IF THERE ARE NO SUCH AGREEMENTS, ARRANGEMENTS OR UNDERSTANDINGS, STATE “NONE” (B) AGREEMENTS, ARRANGEMENTS OR UNDERSTANDINGS RELATING TO OPTIONS OR DERIVATIVES (I) THE VOTING RIGHTS OF ANY RELEVANT SECURITIES UNDER ANY OPTION; OR (II) THE VOTING RIGHTS OR FUTURE ACQUISITION OR DISPOSAL OF ANY RELEVANT SECURITIES TO WHICH ANY DERIVATIVE IS REFERENCED: IF THERE ARE NO SUCH AGREEMENTS, ARRANGEMENTS OR UNDERSTANDINGS, STATE “NONE” (C) ATTACHMENTS PUBLIC DISCLOSURES UNDER RULE 8 OF THE CODE MUST BE MADE TO A REGULATORY INFORMATION SERVICE. THE PANEL’S MARKET SURVEILLANCE UNIT IS AVAILABLE FOR CONSULTATION IN RELATION TO THE CODE’S DISCLOSURE REQUIREMENTS ON +44 (0)20 7638 0129. *IF THE DISCLOSER IS A NATURAL PERSON, A TELEPHONE NUMBER DOES NOT NEED TO BE INCLUDED, PROVIDED CONTACT INFORMATION HAS BEEN PROVIDED TO THE PANEL’S MARKET SURVEILLANCE UNIT. THE CODE CAN BE VIEWED ON THE PANEL’S WEBSITE AT WWW.THETAKEOVERPANEL.ORG.UK.
